Details of the Drug

General Information of Drug (ID: DMDI269)

Drug Name
Docetaxel
Synonyms
EmDOC; TXL; Taxotere; Docetaxel anhydrous; ANX-514; Docetaxel (INN); Docetaxel, Trihydrate; RP-56976; SDP-014; Taxotere (TN); Taxotere(R); XRP-6976L; Docetaxel 114977-28-5; N-debenzoyl-N-Boc-10-deacetyl taxol; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetylpaclitaxel; N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol; (2alpha,5beta,7beta,10beta,13alpha)-4-(acetyloxy)-13-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7,10-trihydroxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; 4-(acetyloxy)-13alpha-({(2R,3S)-3-[(tert-butoxycarbonyl)amino]-2-hydroxy-3-phenylpropanoyl}oxy)-1,7beta,10beta-trihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate
Indication
Disease Entry ICD 11 Status REF
Advanced cancer 2A00-2F9Z Approved [1]
Breast carcinoma N.A. Approved [1]
Head and neck cancer 2D42 Approved [1]
Leiomyosarcoma 2B58 Approved [1]
Lung cancer 2C25.0 Approved [1]
Non-small-cell lung cancer 2C25.Y Approved [1]
Prostate adenocarcinoma N.A. Approved [1]
Prostate cancer 2C82.0 Approved [1]
Solid tumour/cancer 2A00-2F9Z Approved [2]
Urinary system neoplasm N.A. Approved [1]
Gastric cancer 2B72 Investigative [1]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Affected Organisms
Humans and other mammals
ATC Code
L01CD02: Docetaxel
L01CD: Taxanes
L01C: PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 3 Molecular Weight (mw) 807.9
Logarithm of the Partition Coefficient (xlogp) 1.6
Rotatable Bond Count (rotbonds) 13
Hydrogen Bond Donor Count (hbonddonor) 5
Hydrogen Bond Acceptor Count (hbondacc) 14
ADMET Property
BDDCS Class
Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 2: low solubility and high permeability [3]
Clearance
The drug present in the plasma can be removed from the body at the rate of 14 mL/min/kg [4]
Elimination
5% of drug is excreted from urine in the unchanged form [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 4 minutes (alpha), 36 minutes (beta), and 11.1 hours (gamma) [4]
Metabolism
The drug is metabolized via the hepatic []
MRTD
The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.1457 micromolar/kg/day [5]
Unbound Fraction
The unbound fraction of drug in plasma is 0.04% [4]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 2.1 L/kg [4]
Water Solubility
The ability of drug to dissolve in water is measured as 0.0065 mg/mL [3]
Adverse Drug Reaction (ADR)
ADR Term Variation Related DOT DOT ID REF
Leukopenia rs12762549 ABCC2 OTJSIGV5 [6]
Chemical Identifiers
Formula
C43H53NO14
IUPAC Name
[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4-acetyloxy-1,9,12-trihydroxy-15-[(2R,3S)-2-hydroxy-3-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoyl]oxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
Canonical SMILES
CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O
InChI
InChI=1S/C43H53NO14/c1-22-26(55-37(51)32(48)30(24-15-11-9-12-16-24)44-38(52)58-39(3,4)5)20-43(53)35(56-36(50)25-17-13-10-14-18-25)33-41(8,34(49)31(47)29(22)40(43,6)7)27(46)19-28-42(33,21-54-28)57-23(2)45/h9-18,26-28,30-33,35,46-48,53H,19-21H2,1-8H3,(H,44,52)/t26-,27-,28+,30-,31+,32+,33-,35-,41+,42-,43+/m0/s1
InChIKey
ZDZOTLJHXYCWBA-VCVYQWHSSA-N
Cross-matching ID
PubChem CID
148124
ChEBI ID
CHEBI:4672
CAS Number
114977-28-5
UNII
699121PHCA
DrugBank ID
DB01248
TTD ID
D0O5WP
VARIDT ID
DR00251
INTEDE ID
DR0520
ACDINA ID
D01011
Combinatorial Drugs (CBD) Click to Jump to the Detailed CBD Information of This Drug
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tubulin (TUB) TTML2WA NOUNIPROTAC Inhibitor [7]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
TAP-like protein (ABCB9) DT68UV2 ABCB9_HUMAN Substrate [8]
Multidrug resistance-associated protein 7 (ABCC10) DTPS120 MRP7_HUMAN Substrate [9]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [10]
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [11]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [12]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [13]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [14]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [15]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4)
Main DME 		DE4LYSA CP3A4_HUMAN Substrate [16]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [17]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Substrate [17]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Androgen receptor (AR) OTUBKAZZ ANDR_HUMAN Gene/Protein Processing [18]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Gene/Protein Processing [19]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Gene/Protein Processing [20]
Aromatase (CYP19A1) OTZ6XF74 CP19A_HUMAN Gene/Protein Processing [21]
ATP-binding cassette sub-family C member 2 (ABCC2) OTJSIGV5 MRP2_HUMAN Drug Response [6]
ATP-binding cassette sub-family C member 6 (ABCC6) OTZT0LKT MRP6_HUMAN Drug Response [22]
ATP-binding cassette sub-family G member 1 (ABCG1) OT5BG6MK ABCG1_HUMAN Drug Response [22]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Drug Response [23]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Drug Response [24]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Gene/Protein Processing [25]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 02 Neoplasm
Disease Class ICD-11: 2C82 Prostate cancer
The Studied Tissue Lung tissue
The Studied Disease Lung cancer [ICD-11:2C82]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Tubulin (TUB) DTT NO-GeName 5.46E-09 0.28 0.72
P-glycoprotein 1 (ABCB1) DTP P-GP 3.12E-33 -8.30E-01 -1.04E+00
Multidrug resistance-associated protein 1 (ABCC1) DTP MRP1 1.90E-30 1.76E-01 7.31E-01
Multidrug resistance-associated protein 7 (ABCC10) DTP MRP7 2.34E-47 4.95E-01 1.54E+00
Breast cancer resistance protein (ABCG2) DTP BCRP 3.87E-47 -1.28E+00 -1.63E+00
Multidrug resistance-associated protein 2 (ABCC2) DTP MRP2 1.02E-08 -5.12E-02 -2.22E-01
Organic anion transporting polypeptide 1B3 (SLCO1B3) DTP OATP1B3 3.46E-61 1.83E-01 7.90E-01
TAP-like protein (ABCB9) DTP TAPL 2.04E-01 4.47E-02 1.45E-01
Organic anion transporting polypeptide 1B1 (SLCO1B1) DTP OATP1B1 2.80E-34 1.44E-01 9.71E-01
Cytochrome P450 3A5 (CYP3A5) DME CYP3A5 3.12E-38 -1.81E+00 -2.01E+00
Cytochrome P450 3A4 (CYP3A4) DME CYP3A4 5.59E-39 -3.76E-01 -1.64E+00
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Experimental Cancer Drug Sensitivity Information

Cancer Drug Sensitivity Data Curated from 44 Cell Line(s) in Bone Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
RPMI-3460/CS1 GDSC1; GDSC2 -4.5537 3.9782 -5.8923 37.3807
ES8 GDSC1; GDSC2 -10.6992 -8.0822 -10.6993 68.6739
ES7 GDSC1; GDSC2 -10.5023 -6.2951 -10.5093 67.1423
TC71 CTRP2 -10.3208 -6.1169 -10.3215 94.8979
SK-N-MC CTRP2 -9.845 -5.3849 -9.8467 93.2458
ES1 GDSC1; GDSC2 -9.84 -7.7018 -9.891 35.5506
EW-12 GDSC2 -9.6838 -7.8137 -9.7159 33.8957
TC-71 GDSC1; GDSC2 -9.6013 -7.3631 -9.6013 62.5833
SJSA-1 GDSC1; GDSC2 -9.134 -3.2162 -10.5695 34.5363
ES5 GDSC1; GDSC2 -9.0314 -3.3148 -9.1179 58.7775
A-673 GDSC1; GDSC2; CTRP2 -8.6742 -6.9009 -8.6742 65.9099
SK-PN-DW GDSC1; GDSC2 -8.3681 -5.5293 -8.3692 55.6784
EW-1 GDSC1; GDSC2 -8.3217 -5.7283 -8.3223 55.4253
SK-ES-1 GDSC1; GDSC2; CTRP2 -8.1596 -4.5304 -8.1602 63.5533
MHH-ES-1 GDSC1; GDSC2 -7.8699 -0.7596 -8.2009 52.5572
NY GDSC1; GDSC2 -7.6616 -3.8499 -7.6784 51.7181
SaOS-2 GDSC1; GDSC2; CTRP2 -7.4535 -2.1982 -7.4704 60.2183
EW-16 GDSC1; GDSC2 -7.416 -2.4314 -7.5003 50.35
EW-18 GDSC1; GDSC2 -7.3798 -3.2962 -7.4094 50.1583
HOS GDSC1; GDSC2; CTRP2 -7.0489 4.8942 -7.9479 56.6422
HuO9 GDSC1; GDSC2 -6.9558 0.5399 -7.4726 48.0894
EW-3 GDSC1; GDSC2 -6.9269 -0.7163 -7.1924 47.8208
EW-11 GDSC1; GDSC2 -6.8971 3.5162 -8.2629 48.13
EW-22 GDSC1; GDSC2 -5.8549 2.5981 -6.8321 43.1516
CHSA0011 GDSC1; GDSC2 -5.0553 1.2961 -9.1338 13.8521
CAL-78 GDSC1; GDSC2 -4.9011 0.91 -5.3212 37.3154
U-CH2 GDSC2 -4.8174 1.621 -9.1201 13.2108
EW-7 GDSC1; GDSC2 -3.4892 5.0616 -5.177 32.824
CADO-ES1 GDSC1; GDSC2 -3.4039 0.744 -3.6552 28.6295
U2OS GDSC1; GDSC2 -2.4093 7.9928 -5.3478 30.4499
CAL-72 GDSC1; GDSC2 -0.7563 24.1317 -11.6944 36.4827
CHSA0108 GDSC1; GDSC2 -0.5489 8.3072 -9.5703 7.8535
HuO-3N1 GDSC1; GDSC2 -0.2942 22.5156 -10.4849 34.4808
G-292 clone A141B1 GDSC1; GDSC2; CTRP2 -0.0253 10.0236 -1.9717 31.4216
ES6 GDSC1; GDSC2 -0.0067 16.1537 -7.0649 28.9494
MG-63 GDSC1; GDSC2; CTRP2 0.0995 38.4732 -15.3566 42.8195
ES4 GDSC1; GDSC2 0.8381 15.1879 -5.8485 24.9159
CHSA8926 GDSC1; GDSC2 1.0823 20.2227 -8.156 28.9899
EW-24 GDSC1; GDSC2 1.5255 13.2585 -4.3015 19.8325
EW-13 GDSC1; GDSC2 2.9812 5.2972 0.7228 1.3906
H-EMC-SS GDSC1; GDSC2 3.2541 9.3987 -1.0334 6.8486
NOS-1 [Human HNSCC] GDSC1; GDSC2 5.061 17.9888 -3.9317 13.6477
Hs 822.T CTRP2 6.6627 15.0953 2.0233 15.3138
Hs 888.T CTRP2 8.3435 42.3068 -10.2082 34.9219
⏷ Show the Full List of 44 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 196 Cell Line(s) in Haematopoietic And Lymphoid Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MEC1 CTRP2 -12.5504 -2.2218 -12.727 88.604
JM1 GDSC1; GDSC2; CTRP2 -5.6485 -2.0254 -5.6512 52.3554
KMS-20 CTRP2 -15.9176 5.8096 -17.8597 80.2909
MOTN-1 CTRP2 -15.3467 6.6496 -17.4684 79.1364
MJ CTRP2 -14.1495 3.7677 -15.4164 81.296
Hs 611.T CTRP2 -13.3285 7.6424 -15.5549 76.66
HuNS1 CTRP2 -12.8495 0.1447 -13.3153 85.1227
EB1 CTRP2 -12.7147 6.8739 -14.6604 76.8499
KO52 CTRP2 -11.2627 -2.1672 -11.3874 87.9057
BL-70 CTRP2 -10.4345 -9.1802 -10.4345 99.7203
OCI-Ly3 CTRP2 -10.3679 -8.4717 -10.3679 98.9663
Mino CTRP2 -10.304 -9.2869 -10.304 99.8333
M-07e CTRP2 -10.2879 5.1042 -11.5318 76.1747
MOLT-3 CTRP2 -10.2327 -9.2303 -10.2327 99.8165
Pfeiffer CTRP2 -10.212 -4.515 -10.2218 91.7166
SET-2 CTRP2 -10.0815 3.3624 -10.9012 78.1146
F-36P CTRP2 -10.0447 2.8265 -10.7518 78.8042
Ci-1 CTRP2 -9.8652 -2.1992 -9.9375 86.934
OCI-Ly19 GDSC1; GDSC2; CTRP2 -9.699 -7.7512 -9.699 70.4969
Kasumi-2 CTRP2 -9.5389 -1.0931 -9.67 84.5282
DEL GDSC1; GDSC2 -9.4063 -5.0375 -9.422 61.2002
SU-DHL-5 GDSC1; GDSC2 -9.3788 -8.2138 -9.3788 61.346
SIG-M5 GDSC2; CTRP2 -9.3092 -8.9754 -9.3092 68.7535
MV4-11 GDSC1; GDSC2 -9.0843 -7.5081 -9.1142 27.8721
BONNA-12 GDSC2 -9.0004 -6.1006 -9.3084 28.4612
MOLM-13 GDSC1; GDSC2 -8.8777 -7.648 -8.8777 58.5423
JVM-3 GDSC1; GDSC2 -8.8346 -6.4174 -8.8348 58.2949
MLMA GDSC1; GDSC2 -8.8168 -5.0318 -8.825 58.0994
DoHH2 GDSC1; GDSC2 -8.6748 -7.5836 -8.6748 57.4069
RPMI-8226 GDSC1; GDSC2 -8.6665 -7.0628 -8.6665 57.3606
697 GDSC1; GDSC2; CTRP2 -8.6576 -7.7869 -8.6576 65.8359
TALL-1 [Human adult T-ALL] GDSC2 -8.6528 -5.4323 -9.154 26.039
A4/Fukuda GDSC1; GDSC2; CTRP2 -8.6509 -6.6749 -8.6509 65.805
SU-DHL-1 GDSC2 -8.6467 -3.2325 -10.0656 30.3705
MOLT-16 GDSC1; GDSC2 -8.6057 -7.8121 -8.6057 57.0206
IM-9 GDSC1; GDSC2 -8.5859 -7.7008 -8.5859 56.9096
ST486 GDSC1; GDSC2; CTRP2 -8.5691 -7.6031 -8.5691 65.4393
NU-DUL-1 GDSC1; GDSC2 -8.551 -6.7046 -8.6619 22.9428
SU-DHL-6 GDSC1; GDSC2 -8.5408 -6.6424 -8.5409 56.6571
DB GDSC1; GDSC2; CTRP2 -8.5146 -4.2839 -8.5166 65.0488
EoL-1 GDSC1; GDSC2; CTRP2 -8.4977 -7.3255 -8.4977 65.1196
GA-10 GDSC1; GDSC2; CTRP2 -8.4895 -7.3284 -8.4895 65.0828
Namalwa GDSC1; GDSC2; CTRP2 -8.4632 -6.3061 -8.4632 64.9635
SU-DHL-10 GDSC2 -8.455 -7.7116 -8.455 56.1772
U-698-M GDSC1; GDSC2 -8.4376 -7.1092 -8.4376 56.0798
BV-173 GDSC1; GDSC2 -8.403 -6.1843 -8.6321 22.0939
U266B1 GDSC1; GDSC2; CTRP2 -8.3835 -4.2686 -8.3852 64.4897
SUP-M2 GDSC1; GDSC2; CTRP2 -8.3305 -6.1092 -8.3305 64.3691
KMS-12-BM GDSC1; GDSC2 -8.3069 -6.8409 -8.3069 55.3489
OCI-AML-3 GDSC1; GDSC2; CTRP2 -8.2494 -7.6302 -8.2494 64.0079
NB4 GDSC1; GDSC2 -8.2494 -7.1597 -8.2693 19.4434
SR GDSC1; GDSC2 -8.2375 -6.6574 -8.2375 54.9603
SCC-3 GDSC2 -8.207 -5.6277 -8.2076 54.7846
RPMI-6666 GDSC1; GDSC2; CTRP2 -8.2019 -6.3748 -8.2019 63.7946
ATN-1 GDSC1; GDSC2 -8.1921 -6.4811 -8.1921 54.7059
KOPN-8 GDSC1; GDSC2 -8.0825 -6.015 -8.0825 54.0921
RPMI-8866 GDSC1; GDSC2 -8.0218 -5.7839 -8.0219 53.7519
AMO1 GDSC1; GDSC2 -8.0018 -6.2605 -8.0018 53.6415
SEM CTRP2 -7.9664 -5.9209 -7.9664 91.5183
P12-Ichikawa GDSC1; GDSC2 -7.8689 -5.0558 -7.8705 52.8922
WSU-DLCL2 GDSC1; GDSC2 -7.8479 -7.2708 -7.8495 15.3212
JJN-3 GDSC1; GDSC2; CTRP2 -7.847 -6.5693 -7.847 62.2057
NKM-1 GDSC1; GDSC2 -7.7659 -6.5338 -7.8453 14.9029
CRO-AP2 GDSC1; GDSC2 -7.7045 -5.9989 -7.9299 15.0865
BE-13 GDSC1; GDSC2 -7.7016 -2.7649 -7.7725 51.8891
JeKo-1 GDSC1; GDSC2; CTRP2 -7.6982 -5.627 -7.6982 61.5389
ML-2 GDSC1; GDSC2 -7.6694 -5.5069 -7.6696 51.7813
Farage GDSC1; GDSC2 -7.668 -4.3184 -7.675 51.7637
WSU-NHL GDSC1; GDSC2 -7.6675 -5.2351 -7.668 51.7696
BCP-1 CTRP2 -7.6597 -4.4893 -7.6599 88.0343
MOLM-16 GDSC1; GDSC2 -7.6597 -4.3015 -8.5862 18.7135
HuT 78 CTRP2 -7.5953 6.9791 -9.1064 69.8886
EM-2 GDSC1; GDSC2 -7.5952 -4.6374 -7.5981 51.3627
OCI-Ly7 GDSC1; GDSC2 -7.57 -6.4917 -7.6417 12.8975
HL-60 GDSC1; GDSC2; CTRP2 -7.5199 -6.3484 -7.5199 60.7409
ALL-PO GDSC1; GDSC2 -7.4394 -4.5553 -7.4421 50.4935
Loucy GDSC1; GDSC2 -7.4384 -5.7307 -7.4385 50.4893
SKM-1 GDSC1; GDSC2 -7.4309 -5.4479 -7.4309 50.4469
QIMR-WIL GDSC1; GDSC2 -7.4245 -5.0689 -8.0028 14.3498
H9 GDSC1; GDSC2 -7.4178 -3.8105 -7.4314 50.3705
CTB-1 GDSC1; GDSC2 -7.4156 -5.8499 -7.671 12.3709
L-363 GDSC1; GDSC2 -7.4127 -6.0228 -7.4127 50.3453
NOMO-1 GDSC1; GDSC2 -7.4025 -6.0808 -7.4025 50.2882
CTV-1 GDSC1; GDSC2 -7.4024 -5.1906 -7.4027 50.2878
Reh GDSC1; GDSC2 -7.366 -6.1881 -7.366 50.0838
BC-3 GDSC2 -7.3647 -5.8383 -7.6208 11.8672
NU-DHL-1 CTRP2 -7.3508 5.156 -8.3415 71.3984
CCRF-CEM GDSC1; GDSC2 -7.3393 -5.6866 -7.3393 49.9345
Ramos.2G6.4C10 GDSC1; GDSC2 -7.3363 -5.9456 -7.3363 49.9176
ALL-SIL GDSC1; GDSC2 -7.3345 -1.6562 -7.4934 49.9136
CESS GDSC1; GDSC2 -7.3344 -4.3728 -7.338 49.9075
RL GDSC1; GDSC2; CTRP2 -7.256 -5.0233 -7.2561 59.5589
HC-1 GDSC1; GDSC2 -7.2432 -4.9692 -7.2436 49.3971
SUP-B8 GDSC1; GDSC2 -7.2305 -5.6177 -7.5662 10.993
SU-DHL-16 GDSC1; GDSC2 -7.2068 -5.8939 -7.4308 10.1084
MOLT-13 GDSC1; GDSC2 -7.1872 -5.6062 -7.1872 49.0835
MHH-CALL-4 GDSC2 -7.1793 -3.5712 -8.4639 16.2152
MHH-PREB-1 GDSC1; GDSC2 -7.178 -4.9569 -7.1784 49.0323
Hs 445 GDSC2 -7.1576 -4.7427 -7.1583 48.9183
JURL-MK1 GDSC1; GDSC2 -7.1567 -4.2495 -7.1603 48.9153
TUR GDSC1; GDSC2 -7.1161 -5.7301 -7.1161 48.6854
NCI-H929 GDSC1; GDSC2 -7.0737 -5.2343 -7.0737 48.4485
NALM-6 GDSC1; GDSC2 -7.0671 -4.6428 -7.068 48.4125
PL-21 GDSC1; GDSC2 -7.066 -5.817 -7.3115 8.8306
Mono-Mac-6 GDSC1; GDSC2 -7.0555 -3.8368 -8.2185 14.2992
Ku812 GDSC1; GDSC2 -7.0254 -4.4039 -7.0272 48.1804
P32/ISH GDSC1; GDSC2 -7.0002 -6.1474 -7.0002 48.037
KY821 GDSC1; GDSC2 -7.0001 -5.9298 -7.0001 48.0368
MM1.S GDSC1; GDSC2 -6.9804 -4.9119 -6.9806 47.9266
RCH-ACV GDSC1; GDSC2 -6.9802 -5.9059 -7.185 7.7401
CML-T1 GDSC1; GDSC2 -6.9078 -5.4295 -6.9078 47.5204
JVM-2 GDSC1; GDSC2 -6.8968 -3.2809 -6.9157 47.4813
KCL-22 GDSC1; GDSC2 -6.8825 -5.4623 -6.8825 47.3785
Karpas-620 GDSC1; GDSC2 -6.8656 -5.3875 -6.8656 47.2842
WIL2 NS GDSC1; GDSC2 -6.8391 -4.6273 -6.8396 47.1367
RS4;11 GDSC1; GDSC2 -6.8206 -4.779 -6.8208 47.0327
Jiyoye GDSC1; GDSC2 -6.7947 -2.6301 -6.8397 46.9434
CMK GDSC1; CTRP2 -6.7938 -4.1969 -6.7939 63.0268
EJM GDSC1; GDSC2; CTRP2 -6.7672 -3.8436 -6.7674 57.3663
KE-37 GDSC1; GDSC2 -6.7262 -4.6594 -6.7265 46.5046
RPMI-8402 GDSC1; GDSC2 -6.6882 -5.7939 -6.9304 5.0693
BC-1 GDSC1; GDSC2 -6.6639 -5.5043 -6.6639 46.1552
MEG-01 GDSC1; GDSC2 -6.6604 -4.2175 -6.6618 46.1386
Sc-1 GDSC1 -6.6527 -5.9518 -6.8237 5.3445
MC116 GDSC1; GDSC2 -6.6343 -5.0925 -7.2131 6.6215
Jurkat GDSC1; GDSC2 -6.6053 -5.2372 -6.6054 45.8278
ARH-77 GDSC1; GDSC2 -6.5805 -4.6546 -6.5807 45.6893
P31/FUJ GDSC1; GDSC2 -6.5235 -4.0971 -7.6065 8.737
VAL GDSC1; GDSC2 -6.5178 -4.6251 -6.5179 45.3382
A3/Kawakami GDSC1; GDSC2; CTRP2 -6.5134 -5.9335 -6.5134 56.2338
MY-M12 GDSC1; GDSC2 -6.4923 -0.6601 -9.2961 18.675
OCI-AML-2 GDSC1; GDSC2 -6.4876 -5.3898 -6.4876 45.1692
HT GDSC1; GDSC2 -6.4706 -4.1719 -7.5232 8.0485
GDM-1 GDSC1; GDSC2 -6.4584 -3.8044 -6.4614 45.012
BALL-1 GDSC1; GDSC2 -6.4484 -5.3541 -6.4484 44.9496
DG-75 GDSC1; GDSC2 -6.4472 -3.9328 -6.4493 44.9476
L-540 GDSC1; GDSC2 -6.4155 -3.2814 -6.4259 44.7868
SU-DHL-4 GDSC1; GDSC2 -6.4125 -4.2456 -7.4365 7.324
OCI-AML-5 GDSC1; GDSC2; CTRP2 -6.3644 -5.3062 -6.3644 55.5666
K-562 GDSC1; GDSC2; CTRP2 -6.2993 -2.6641 -6.3012 55.262
KM-H2 GDSC1; GDSC2 -6.2551 -4.0647 -6.2559 43.87
LC4-1 GDSC1; GDSC2 -6.2285 -3.8221 -6.2302 43.7233
YT GDSC1; GDSC2 -6.163 -4.0387 -7.334 5.9604
OCI-M1 GDSC1; GDSC2; CTRP2 -6.1592 0.1923 -6.2428 54.4526
LAMA-84 GDSC1; GDSC2 -6.1291 -1.8063 -6.2055 43.3161
OPM-2 GDSC1; GDSC2; CTRP2 -6.1169 -4.8007 -6.1169 54.4586
SUP-B15 GDSC1; GDSC2; CTRP2 -5.9805 -2.6031 -5.9818 53.8422
Kasumi-1 GDSC1; GDSC2; CTRP2 -5.9657 -0.1348 -6.0226 53.6687
Raji GDSC1; GDSC2 -5.8909 -1.9748 -5.9439 41.9505
Karpas-231 GDSC1; GDSC2 -5.6944 -3.4196 -5.6962 40.7355
JSC-1 GDSC1; GDSC2 -5.6912 -1.2653 -5.7971 40.9547
Daudi GDSC1; GDSC2; CTRP2 -5.6532 -1.5404 -5.6604 52.3694
MOLP-8 GDSC1; GDSC2; CTRP2 -5.6339 -0.8704 -5.6536 52.2687
SK-MM-2 GDSC1; GDSC2 -5.6231 -4.5005 -5.6231 40.3317
HDLM-2 GDSC1; GDSC2 -5.6068 -2.0232 -5.646 40.3381
Karpas-299 GDSC1; GDSC2 -5.463 -1.5679 -5.5284 39.5986
HAL-01 GDSC1; GDSC2 -5.3387 -3.8318 -5.3388 38.7407
EHEB GDSC1 -5.3058 -1.689 -7.856 8.7906
CA46 GDSC1; GDSC2; CTRP2 -5.183 -1.3948 -5.1882 50.2757
SUP-T1 GDSC1; GDSC2 -4.7633 0.8056 -5.1469 36.485
Granta-519 GDSC1; GDSC2; CTRP2 -4.7559 1.6041 -4.8915 48.4319
HEL 92.1.7 CTRP2 -4.5903 4.7181 -5.2281 64.4591
VL51 GDSC1; GDSC2 -4.186 1.3992 -4.6633 33.5676
Karpas-422 GDSC1; GDSC2; CTRP2 -4.1606 2.9575 -4.427 45.9672
MHH-CALL-2 GDSC1; GDSC2 -4.1574 0.7404 -4.4731 32.9911
L-428 GDSC1; GDSC2; CTRP2 -4.066 1.2368 -4.1381 45.3691
GR-ST GDSC1; GDSC2 -3.6961 4.1291 -5.0292 33.0536
SUP-HD1 GDSC1; GDSC2; CTRP2 -3.6155 4.7382 -4.1719 43.9515
TK [Human B-cell lymphoma] GDSC1; GDSC2 -3.4625 2.8396 -4.3108 30.608
KG-1 GDSC1; GDSC2 -3.3522 1.6206 -3.8129 28.9378
RC-K8 GDSC1; GDSC2 -3.2101 4.4404 -4.6326 30.7631
EB2 GDSC1; GDSC2 -3.1719 4.734 -4.7095 30.8551
LP-1 GDSC1; GDSC2; CTRP2 -3.1216 3.4305 -3.3853 41.4884
Karpas-45 GDSC1; GDSC2 -2.7473 6.4837 -5.009 30.4913
HEL GDSC1; GDSC2 -2.6563 3.9345 -3.8452 27.2076
L-1236 GDSC1; GDSC2 -1.8623 14.2402 -7.8037 33.8292
AML-193 CTRP2 -1.6882 57.5387 -26.4002 50.2096
P30/OHK GDSC1; GDSC2 -1.5091 6.3749 -3.7055 24.0593
OCI-Ly10 CTRP2 -1.5019 67.2059 -31.0323 50.0328
HH [Human lymphoma] GDSC1; GDSC2; CTRP2 -0.8075 5.8114 -1.3709 31.9243
TF-1 CTRP2 -0.5664 647.7304 -320.3241 49.9242
THP-1 GDSC1; GDSC2 -0.3026 3.4392 -7.527 0.49
KMS-11 GDSC1; GDSC2 -0.2012 3.2459 -7.4251 0.3145
HD-MY-Z CTRP2 -0.1447 86.6088 -39.505 49.1693
Karpas-1106P GDSC1; GDSC2 0.0507 11.7079 -4.8058 23.8436
ROS-50 GDSC1; GDSC2 0.0602 3.9198 -7.5625 0.4582
NK-92MI GDSC2 0.1941 4.0671 -7.5655 0.4319
PF-382 GDSC1; GDSC2 0.2728 8.338 -2.939 18.0093
ME1 GDSC1; GDSC2 0.3662 8.7539 -3.0598 18.2155
KMOE-2 GDSC1; GDSC2 0.464 9.2234 -3.2044 18.4858
MN-60 GDSC1; GDSC2 0.4956 9.9122 -3.5181 19.3896
SU-DHL-8 GDSC2 0.5148 8.7816 -2.94 17.5578
DND-41 GDSC1; GDSC2; CTRP2 3.1523 12.7258 0.0677 20.8311
Toledo CTRP2 3.4817 6.4001 3.143 18.2723
MOLT-4 GDSC1; GDSC2 4.1261 5.8069 1.041 0.1517
BL-41 GDSC1; GDSC2; CTRP2 8.4012 19.5098 1.1606 10.8544
⏷ Show the Full List of 196 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 27 Cell Line(s) in Oesophagus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TE15 CTRP2 -13.8328 3.3731 -14.9815 81.5381
TE-11 GDSC1; GDSC2; CTRP2 -10.7492 -6.1622 -10.7505 74.5683
EC-GI-10 GDSC1; GDSC2; CTRP2 -9.9412 4.0516 -10.9002 64.8507
KYSE-180 GDSC1; GDSC2 -8.946 -6.0628 -8.9468 58.8996
T.T GDSC1; GDSC2 -8.7962 -5.0412 -9.4548 28.2375
TE-10 GDSC1; GDSC2 -8.5558 -0.9941 -11.0178 33.4621
TE-8 GDSC1; GDSC2 -8.3341 -2.2018 -8.4894 55.0628
TE-9 GDSC1; GDSC2 -8.2952 1.4547 -9.1623 54.0326
TE-4 GDSC1; GDSC2 -8.2706 -5.2231 -8.2728 55.1277
OE21 GDSC1; GDSC2; CTRP2 -7.0733 3.4022 -7.6462 57.1757
TE-15 GDSC1; GDSC2 -6.9175 -3.8563 -6.9237 47.5825
KYSE-270 GDSC1; GDSC2 -6.8516 -3.5269 -6.863 47.2213
KYSE-510 GDSC1; GDSC2; CTRP2 -6.446 16.9133 -11.5598 52.8545
TE-1 GDSC1; GDSC2 -6.1188 1.6404 -6.8376 44.1389
TE-14 CTRP2 -6.0563 10.6782 -8.6642 63.6449
TE-5 GDSC1; GDSC2; CTRP2 -5.1408 7.6849 -6.6468 50.0651
KYSE-410 GDSC1; GDSC2 -3.7695 5.5952 -5.6904 34.7025
TE-6 GDSC1; GDSC2 -1.9031 8.7908 -5.2197 28.965
KYSE-140 GDSC1; GDSC2 -0.8038 22.9865 -11.1664 36.0458
COLO 680N GDSC1; GDSC2 0.8226 14.1959 -5.3666 23.8164
KYSE-450 GDSC1; GDSC2; CTRP2 1.2608 19.6403 -5.0599 33.849
KYSE-520 GDSC1; GDSC2; CTRP2 1.3147 20.6004 -5.4725 34.2797
OE19 GDSC1; GDSC2; CTRP2 2.3728 22.607 -5.4656 32.5119
KYSE-150 GDSC1; GDSC2; CTRP2 2.7062 34.7337 -11.169 37.4557
OE33 GDSC1; GDSC2; CTRP2 4.96 25.8923 -4.7971 27.7111
KYSE-70 GDSC1; GDSC2 5.8828 18.7237 -3.7214 12.0765
KYSE-30 CTRP2 15.0381 59.3146 -13.5178 30.7913
⏷ Show the Full List of 27 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 34 Cell Line(s) in Pancreas Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
N2a-PK1 CTRP2 -5.3561 19.4587 -11.5388 58.2459
KP-4 GDSC1; GDSC2 -8.2263 -5.5188 -8.2272 54.8903
PaTu 8988t GDSC1; GDSC2 -5.2736 1.4333 -5.8591 39.6359
Panc 03.27 GDSC1; GDSC2; CTRP2 -4.8602 8.3439 -6.555 49.1464
CFPAC-1 GDSC1; GDSC2 -4.3058 4.4906 -5.8186 36.4946
MZ-PC-1 GDSC1; GDSC2 -4.3033 7.5048 -11.6335 22.6897
MIA PaCa-2 GDSC1; GDSC2; CTRP2 -3.8111 13.2451 -7.2724 46.3888
PSN1 GDSC1; GDSC2; CTRP2 -2.6052 7.6352 -3.873 40.6843
PL4 GDSC1; GDSC2 -2.5633 9.237 -6.0773 32.3745
HuP-T4 GDSC1; GDSC2 -2.3309 6.6098 -4.6404 28.5509
BxPC-3 GDSC1; GDSC2 -1.7838 9.1372 -5.2674 28.8054
DAN-G GDSC1; GDSC2; CTRP2 -1.6373 16.1424 -6.2759 40.7631
PaTu 8988s CTRP2 -1.0905 40.903 -17.6376 49.5219
QGP-1 GDSC1; GDSC2 -0.4845 15.1759 -7.0038 29.7284
KP-1N GDSC1; GDSC2 -0.3903 12.2918 -5.4922 26.3892
Panc 08.13 GDSC1; GDSC2; CTRP2 -0.1853 12.028 -2.9758 33.5831
KP-3 GDSC1; GDSC2 -0.1829 7.4686 -2.9346 18.8829
Capan-1 GDSC1; GDSC2; CTRP2 0.0222 12.5256 -2.9776 33.1482
Panc 10.05 GDSC1; GDSC2; CTRP2 0.5934 19.8167 -5.7828 35.9189
PaTu 8902 GDSC1; GDSC2 1.0168 18.2989 -7.2501 27.4988
SW1990 GDSC1; GDSC2; CTRP2 1.0381 14.2171 -2.7101 30.6458
HPAF-II GDSC1; GDSC2 1.1519 9.7621 -2.8698 16.1886
HPAC GDSC1; GDSC2 1.3644 17.1038 -6.359 25.1312
SUIT-2 GDSC1; GDSC2 1.7936 8.3289 -1.6148 10.9244
KP-2 GDSC1; GDSC2; CTRP2 2.7058 28.2109 -7.9309 34.7929
Panc 02.03 GDSC1; GDSC2; CTRP2 3.1733 29.9657 -8.3858 34.5752
PK-45H CTRP2 3.2892 22.6363 -4.6464 37.5284
Hs 766T GDSC1; GDSC2; CTRP2 4.1883 22.4328 -3.7437 27.1297
SU.86.86 GDSC1; GDSC2 4.212 18.489 -4.7901 17.0707
AsPC-1 GDSC1; GDSC2; CTRP2 4.3394 15.856 -0.3459 19.9413
HuP-T3 GDSC1; GDSC2; CTRP2 5.7277 22.0243 -2.211 22.0737
YAPC GDSC1; GDSC2 7.013 25.6367 -6.2729 17.1365
Panc 04.03 GDSC1; GDSC2; CTRP2 7.5985 22.7043 -1.0284 17.1164
Capan-2 GDSC1; GDSC2; CTRP2 10.8034 31.029 -2.7381 17.1611
⏷ Show the Full List of 34 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 11 Cell Line(s) in Aero Dig Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
KYSE-220 GDSC1; GDSC2 -9.9471 -5.223 -9.9671 63.9678
FLO-1 GDSC1; GDSC2 -9.6543 -4.5037 -9.6928 62.2436
OACP4 C GDSC1; GDSC2 -8.5312 -4.5779 -8.5442 56.5057
HCE-4 GDSC1; GDSC2 -7.9951 -5.0275 -8.6124 20.2093
OACM5.1 C GDSC1; GDSC2 -5.9232 -1.6375 -6.0046 42.1875
ESO-26 GDSC1; GDSC2 -5.8752 -2.3187 -5.9072 41.8178
TE-12 GDSC1; GDSC2 -2.1892 8.6411 -5.4303 30.114
KYSE-50 GDSC1; GDSC2 -0.8157 15.4726 -7.4486 31.1582
SK-GT-4 GDSC1; GDSC2 -0.2073 19.6542 -8.9835 32.4302
ESO-51 GDSC1; GDSC2 2.2515 13.876 -4.0143 17.8356
KYAE-1 GDSC1; GDSC2 4.182 5.7121 1.094 0.0924
⏷ Show the Full List of 11 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Ascites Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
COLO 684 GDSC1; GDSC2; CTRP2 -3.2533 5.6871 -4.0071 42.6753
Cancer Drug Sensitivity Data Curated from 35 Cell Line(s) in Autonomic Ganglia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NH-6 CTRP2 -12.4339 28.7101 -22.8651 64.072
SJNB-14 GDSC1; GDSC2 -10.4715 -7.5036 -10.4718 67.3599
IMR-32 CTRP2 -10.0925 -8.7252 -10.0925 99.372
SJNB-13 GDSC1; GDSC2 -9.6525 -6.1512 -9.6553 62.7481
SK-N-MC-IXC GDSC1; GDSC2 -9.4384 -7.7224 -9.4668 31.4164
SJNB-17 GDSC1; GDSC2 -8.8184 -4.7457 -9.5947 29.0244
Kelly GDSC1; GDSC2 -8.2613 -4.2754 -8.2772 55.0173
CHP-212 GDSC1; GDSC2; CTRP2 -7.9842 -2.0667 -8.0135 62.3457
NB69 GDSC1; GDSC2 -7.5969 -3.7616 -7.6149 51.3595
KP-N-YS GDSC1; GDSC2 -7.3532 -0.7331 -10.0163 25.0523
IMR-5 GDSC1; GDSC2 -6.9048 -5.3579 -6.9048 47.5036
SJNB-10 GDSC1; GDSC2 -6.9033 -2.7929 -6.9429 47.5371
MHH-NB-11 GDSC1; GDSC2 -6.3443 -2.6832 -8.16 11.6601
SK-N-DZ GDSC1; GDSC2; CTRP2 -6.3058 2.0537 -6.5911 54.7617
TGW GDSC1; GDSC2 -6.2293 -3.4076 -6.2351 43.7371
SJNB-6 GDSC1; GDSC2 -6.1951 -3.1017 -7.8276 9.1597
NB1 GDSC1; GDSC2 -6.0926 -1.2661 -8.6613 13.9469
SJNB-12 GDSC1; GDSC2 -5.7969 -0.707 -8.7047 13.3782
SK-N-SH GDSC1; GDSC2 -5.5716 2.3871 -10.068 19.7853
SJNB-5 GDSC1; GDSC2 -5.4664 5.3189 -11.4456 24.8828
KP-N-RT-BM-1 GDSC2 -5.3877 -0.3984 -8.5457 11.3991
SK-N-FI GDSC1; GDSC2; CTRP2 -4.5578 3.2922 -4.9076 47.6899
NH-12 GDSC1; GDSC2 -4.5234 6.2176 -6.7386 38.7115
SK-N-AS GDSC1; GDSC2; CTRP2 -4.4306 4.9962 -5.119 47.3352
SiMa GDSC1; GDSC2 -4.2949 3.0976 -5.3005 35.3972
NB(TU)1 GDSC1; GDSC2 -3.2642 0.8262 -3.5209 27.8664
LA-N-6 GDSC1; GDSC2 -1.3829 6.9497 -9.4339 8.4123
SK-N-BE(2) CTRP2 -1.1321 97.9031 -45.9945 49.8182
SK-N-BE(2)-M17 GDSC1; GDSC2 -1.0312 13.5719 -6.7075 30.2428
GOTO GDSC1; GDSC2 0.0231 10.1601 -4.0649 21.8892
CHP-134 GDSC2 0.1101 16.4162 -7.0929 28.7889
CHP-126 GDSC1; GDSC2 0.3751 2.6458 -7.039 0.0159
SJNB-7 GDSC1; GDSC2 1.8452 16.3467 -5.5802 22.5821
GI-ME-N GDSC1; GDSC2 5.5557 27.3781 -8.1705 22.67
KP-N-YN GDSC1; GDSC2; CTRP2 7.7602 9.8271 5.3194 0.6302
⏷ Show the Full List of 35 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 2 Cell Line(s) in Biliary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuCC-T1 GDSC1; GDSC2 0.6901 18.0785 -7.4189 28.3661
SNU-869 CTRP2 4.6255 70.228 -27.2374 44.9478
Cancer Drug Sensitivity Data Curated from 86 Cell Line(s) in Breast Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SK-BR-3 CTRP2 -9.6089 10.4151 -12.4043 70.0436
HCC1806 GDSC1; GDSC2 -9.272 -5.8321 -9.2751 60.5425
JIMT-1 GDSC1; GDSC2 -8.522 -3.9775 -8.553 56.2659
Hs 578T GDSC1; GDSC2; CTRP2 -8.3354 1.4077 -8.6689 62.0219
CAL-148 GDSC2 -8.3217 -6.6523 -8.4239 20.5256
AU565 GDSC1; GDSC2; CTRP2 -7.9729 -3.6333 -7.9761 62.5507
HCC2157 GDSC1; GDSC2 -7.8075 -4.0643 -7.8211 52.4257
OCUB-M GDSC1; GDSC2 -7.6867 -2.7844 -7.7556 51.7136
HCC1187 GDSC1; GDSC2 -7.5292 -1.9372 -7.6671 50.8457
CAL-51 GDSC1; GDSC2 -7.0725 -2.7591 -7.1197 48.3817
MRK-nu-1 GDSC1; GDSC2 -6.9002 -4.1788 -6.9028 47.3885
DU4475 GDSC1; GDSC2; CTRP2 -6.7809 -1.2724 -6.8108 57.1623
HCC1599 GDSC2 -6.6141 -4.3227 -7.5744 8.7907
MDA-MB-468 GDSC1; GDSC2; CTRP2 -6.4322 2.8633 -6.8537 55.0053
HCC1395 GDSC1; GDSC2 -6.0551 -3.3759 -7.5789 7.1882
HCC1954 GDSC1; GDSC2 -5.8396 -1.0188 -5.9836 41.7679
Evsa-T GDSC1; GDSC2 -5.2765 5.0521 -7.0704 41.4094
BT-549 GDSC1; GDSC2; CTRP2 -5.221 7.9009 -6.8028 50.2698
CAL-85-1 GDSC1; GDSC2; CTRP2 -5.1669 3.4232 -5.5878 50.1123
UACC-812 GDSC2 -5.0374 2.0539 -9.4935 15.6195
EFM-19 GDSC1; GDSC2 -4.9836 5.7595 -7.037 40.4508
UACC-893 GDSC1; GDSC2 -4.9161 5.8686 -11.2889 22.9099
MDA-MB-175-VII GDSC1; GDSC2 -4.6308 3.6515 -9.9791 16.9545
CAMA-1 GDSC1; GDSC2 -4.6246 4.602 -6.2018 38.088
MDA-MB-157 GDSC1; GDSC2; CTRP2 -3.9295 3.8322 -4.3261 45.0386
CAL-120 GDSC1; GDSC2 -3.7673 5.6196 -5.6982 34.6543
HCC38 GDSC1; GDSC2; CTRP2 -3.1645 7.8002 -4.5346 42.9025
HCC1143 GDSC1; GDSC2 -2.9568 8.3122 -6.0421 33.2142
BT-20 GDSC1; GDSC2; CTRP2 -2.7963 10.1508 -4.9699 42.3033
EFM-192A GDSC1; GDSC2; CTRP2 -1.905 6.9905 -2.9066 37.412
MDA-MB-330 GDSC1; GDSC2 -0.99 9.862 -4.8559 26.0243
MFM-223 GDSC1; GDSC2 -0.8453 11.6827 -5.6091 27.5318
BT-474 GDSC1; GDSC2; CTRP2 -0.8268 9.6679 -2.6816 34.4505
MCF-7 GDSC1; GDSC2 -0.7777 17.7614 -8.5478 32.7871
MDA-MB-453 GDSC1; GDSC2; CTRP2 -0.6523 16.8775 -5.6203 38.0659
HCC70 GDSC1; GDSC2 -0.0912 21.3292 -9.7166 33.1832
BT-483 GDSC1; GDSC2 -0.078 6.2673 -8.4852 3.0416
YMB-1-E GDSC2 -0.0536 6.6616 -8.6308 3.5595
HDQ-P1 GDSC1; GDSC2 0.3156 13.8997 -5.6598 25.392
MDA-MB-436 GDSC1; GDSC2 0.7746 15.4544 -6.0361 25.4117
COLO 824 GDSC1; GDSC2 1.2853 15.9797 -5.8637 24.1409
HCC202 GDSC1; GDSC2; CTRP2 1.9077 13.9076 -1.7051 27.0314
HCC1569 GDSC1; GDSC2 2.3486 22.4789 -8.2326 27.1088
HCC1500 GDSC1; GDSC2; CTRP2 2.4394 13.7663 -1.118 24.8185
MDA-MB-231 GDSC1; GDSC2 2.4991 21.2537 -7.4984 25.5705
HCC1937 GDSC1; GDSC2 2.5428 14.5818 -4.1335 17.6886
HCC1419 GDSC1; GDSC2; CTRP2 4.5447 12.3077 1.5894 14.6119
HCC2218 GDSC1; GDSC2; CTRP2 6.642 21.4679 -1.1752 18.6176
MDA-MB-361 GDSC1; GDSC2; CTRP2 8.1607 26.0143 -2.2363 19.0149
Hs 578Bst CTRP2 8.583 36.2388 -6.9928 31.5139
MDA-MB-415 GDSC1; GDSC2; CTRP2 9.2773 35.7536 -6.2095 24.518
T-47D GDSC1; GDSC2; CTRP2 9.559 35.5251 -5.8791 23.7437
ZR-75-30 GDSC1; GDSC2; CTRP2 11.5893 28.9232 -1.1689 13.1768
HCC1428 GDSC1; GDSC2; CTRP2 14.6605 31.7957 -0.5564 9.3266
BT 231 CTRP2 -14.0442 12.9677 -18.0949 73.0114
BT 145 CTRP2 -13.2996 9.7036 -16.168 74.815
BT 112 CTRP2 -11.6562 37.2618 -25.9827 61.1526
BT164 CTRP2 -11.0821 37.3517 -25.457 60.6441
BT 416 CTRP2 -7.6187 6.2756 -8.9303 70.6682
BT 179 CTRP2 -2.893 47.2976 -22.4336 51.5531
BT 245 CTRP2 -0.6024 34.3478 -13.9675 48.6758
BT 428 CTRP2 0.0966 118.9662 -55.4465 49.2815
BT 359 CTRP2 0.3757 83.8267 -37.6662 48.7954
BT 131 CTRP2 0.543 717.1353 -354.0959 49.8464
BT 159 CTRP2 1.0022 76.948 -33.6922 48.2263
BT 286 CTRP2 1.7783 96.0604 -42.5663 48.1186
BT 271 CTRP2 3.5737 68.4495 -27.2402 45.7702
BT 224 CTRP2 3.6075 38.5816 -12.2971 42.246
BT 239 CTRP2 5.7651 54.07 -18.2015 41.9324
BT 498 CTRP2 7.3551 8.5266 5.6525 0.2916
BT 320 CTRP2 7.4261 8.4544 5.7079 0.1587
BT 422 CTRP2 8.2149 29.1465 -3.7514 27.4946
BT 248 CTRP2 8.5384 41.9856 -9.8924 34.4275
BT 139 CTRP2 8.578 52.3527 -15.0337 37.7982
BT 482 CTRP2 9.0901 19.9848 1.4203 13.4308
BT147 CTRP2 9.6997 59.5745 -17.7388 38.0525
BT 216 CTRP2 9.8583 42.4891 -9.1052 32.1465
BT 187 CTRP2 10.085 43.4752 -9.4195 32.1838
BT 330 CTRP2 10.2061 58.1903 -16.6466 37.0715
BT 444 CTRP2 11.2791 39.5584 -6.5753 27.5953
BT 228 CTRP2 12.0267 52.737 -12.523 32.7712
BT 440 CTRP2 12.7414 45.0813 -8.213 27.9706
BT 232 CTRP2 13.4197 46.3038 -8.3186 27.3804
BT 333 CTRP2 13.5026 39.6544 -5.0241 22.7689
BT 328 CTRP2 15.5994 37.7449 -2.7267 16.3651
BT 340 CTRP2 15.9232 44.6167 -5.7602 21.4175
⏷ Show the Full List of 86 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 57 Cell Line(s) in Central Nervous System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
D-566MG GDSC1; GDSC2 -11.1339 -8.164 -11.2087 48.3729
MOG-G-UVW GDSC1; GDSC2 -11.0816 -7.1723 -11.3112 48.0202
MOG-G-CCM GDSC1; GDSC2 -10.7285 -6.6152 -11.0541 44.9844
Daoy GDSC1; GDSC2 -9.4741 -7.1221 -9.4742 61.8697
Hs 683 GDSC1; GDSC2; CTRP2 -9.4358 -6.4334 -9.4358 69.2799
NMC-G1 GDSC1; GDSC2 -9.285 4.9187 -14.5691 42.6073
YH-13 GDSC1; GDSC2 -9.1983 -4.7577 -9.2177 60.057
D-336MG GDSC1; GDSC2 -8.835 -5.5312 -9.3149 27.7122
D-423MG GDSC1; GDSC2 -8.8213 -3.9189 -9.9419 30.6278
D-247MG GDSC1; GDSC2 -8.8188 -4.0904 -9.866 30.2821
GaMG GDSC1; GDSC2 -8.7838 -5.2799 -8.7886 57.9502
H4 GDSC1; GDSC2 -8.7442 -5.3991 -8.7476 57.745
SF539 GDSC1; GDSC2; CTRP2 -8.7335 2.2772 -9.2329 62.8315
D283 Med GDSC1; GDSC2; CTRP2 -8.543 2.9317 -9.1462 61.9282
Becker GDSC1; GDSC2; CTRP2 -8.2947 -4.7454 -8.2951 64.1604
GI-1 GDSC1; GDSC2 -8.1 -1.654 -8.3085 53.8068
M059J GDSC1; GDSC2 -8.0061 -2.4442 -8.1181 53.4546
PFSK-1 GDSC1; GDSC2 -7.9268 0.262 -8.4665 52.6831
SF126 GDSC1; GDSC2 -7.4741 -5.2422 -7.9787 14.4035
SK-MG-1 GDSC1; GDSC2 -7.119 -1.6152 -7.2695 48.7733
ONS-76 GDSC1; GDSC2 -7.0903 -0.733 -7.3654 48.6685
LNZTA3WT4 GDSC1; GDSC2 -6.9008 -3.6082 -8.187 13.578
D-502MG GDSC1; GDSC2 -6.8089 0.0682 -9.9313 22.8247
Onda 10 GDSC1; GDSC2 -6.6933 -1.8806 -8.8592 16.9047
SF295 GDSC1; GDSC2 -6.3557 -3.219 -7.9016 10.0866
42-MG-BA GDSC1; GDSC2; CTRP2 -6.2932 43.768 -23.8787 51.2605
A-172 GDSC1; GDSC2; CTRP2 -5.9342 8.5447 -7.7874 52.5087
KALS-1 GDSC1; GDSC2 -5.3745 2.4192 -6.2533 40.6564
D-245MG GDSC2 -5.2486 1.5292 -9.3928 15.6846
SW1088 GDSC1; GDSC2 -5.0841 5.9977 -7.2389 41.0772
D-263MG GDSC1; GDSC2 -4.9312 9.3648 -8.515 41.9919
LN-18 GDSC1; GDSC2 -4.7815 1.7474 -5.408 37.1251
KNS-81-FD GDSC1; GDSC2 -4.707 6.2829 -11.3343 22.6126
KS-1 [Human Krukenberg tumour] GDSC1; GDSC2 -4.312 9.5939 -7.9887 39.7829
DK-MG GDSC1; GDSC2; CTRP2 -3.2967 6.1839 -4.1883 42.9996
D-542MG GDSC1; GDSC2 -2.0956 7.9301 -10.309 13.2793
U-118MG GDSC1; GDSC2; CTRP2 -2.071 8.3502 -3.534 38.8334
YKG-1 GDSC1; GDSC2; CTRP2 -1.7596 20.1786 -8.2484 42.4157
8-MG-BA GDSC1; GDSC2 -1.0428 36.7932 -18.2542 41.1345
AM-38 GDSC1; GDSC2 -0.9542 7.7022 -3.782 23.0635
KG-1-C CTRP2 -0.8949 36.9937 -15.5356 49.1925
Onda 11 GDSC1; GDSC2 -0.7601 8.6789 -9.8511 9.2929
SF268 GDSC1; GDSC2; CTRP2 -0.1896 28.6406 -10.7928 41.2191
CCF-STTG1 CTRP2 -0.1089 53.875 -23.1744 48.6355
LN-229 GDSC1; GDSC2 -0.07 9.5134 -3.8307 21.3971
U-251MG GDSC1; GDSC2; CTRP2 0.077 17.6119 -5.2398 36.2479
DBTRG-05MG GDSC1; GDSC2 1.1589 16.8454 -6.4031 25.572
D-392MG GDSC1; GDSC2 1.3364 16.0687 -5.865 24.0912
CAS-1 GDSC1; GDSC2 1.4345 14.1214 -4.8091 21.3507
GB-1 GDSC1; GDSC2 2.8924 20.9932 -7.0522 24.1502
LN-405 GDSC1; GDSC2 2.9204 18.9045 -5.9886 21.8445
U-87MG ATCC GDSC1; GDSC2 3.181 16.8576 -4.7655 18.4678
KINGS-1 GDSC1; GDSC2 3.3954 23.7801 -8.0422 25.2874
SNB-75 GDSC1; GDSC2; CTRP2 4.872 30.9793 -7.4131 31.2845
SW1783 GDSC1; GDSC2; CTRP2 5.188 7.4335 4.5509 5.4802
KNS-42 GDSC1; GDSC2; CTRP2 12.111 50.5449 -11.3744 27.7837
T98G GDSC1; GDSC2; CTRP2 13.0457 34.9711 -3.0821 15.6891
⏷ Show the Full List of 57 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Digestive System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
TGBC1TKB GDSC1; GDSC2 -5.825 -1.413 -8.3756 11.518
TGBC24TKB GDSC1; GDSC2 -5.6425 -0.0622 -5.9216 41.0292
ETK-1 GDSC1; GDSC2 -5.5794 7.5558 -8.4015 43.7467
Cancer Drug Sensitivity Data Curated from 12 Cell Line(s) in Endometrium Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
JHUEM-7 CTRP2 -12.6584 2.6209 -13.5441 81.6182
RL95-2 GDSC1; GDSC2 -8.5599 -0.4114 -9.0122 55.6336
ESS-1 GDSC1; GDSC2; CTRP2 -7.9018 -0.506 -8.007 61.4895
JHUEM-3 CTRP2 -7.7126 17.3126 -13.0491 62.9556
JHUEM-1 CTRP2 -6.0759 8.1662 -7.8176 65.5677
MFE-319 GDSC1; GDSC2; CTRP2 -4.4823 8.1851 -6.0922 47.8606
MFE-296 GDSC1; GDSC2; CTRP2 -3.8915 5.4179 -4.6345 45.2381
AN3-CA GDSC1; GDSC2; CTRP2 -1.3431 21.5701 -8.4921 41.7872
HEC-1-A CTRP2 -0.8767 49.9435 -21.9099 49.3742
MFE-280 GDSC1; GDSC2 0.1006 7.5349 -2.7024 17.5786
KLE GDSC1; GDSC2 3.1467 16.4716 -4.6002 18.0818
EN GDSC1; GDSC2; CTRP2 12.4618 36.5566 -4.2508 18.2963
⏷ Show the Full List of 12 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 36 Cell Line(s) in Kidney Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SW13 GDSC1; GDSC2 -8.4671 -4.6161 -8.4783 56.1639
KTCTL-140 GDSC1; GDSC2 -8.3631 -5.7189 -8.7392 22.5006
BB65-RCC GDSC1; GDSC2 -7.5238 -1.273 -9.9067 25.1686
KTCTL-21 GDSC1; GDSC2 -6.5713 -2.211 -8.5887 14.9453
LB2241-RCC GDSC1; GDSC2 -6.259 -3.3071 -7.7773 9.0254
KTCTL-13 GDSC1; GDSC2 -6.2112 -3.8672 -7.4583 6.8786
LB996-RCC GDSC2 -6.0116 1.9626 -6.8116 43.7039
KTCTL-1M GDSC1; GDSC2 -5.8478 -1.7267 -8.2374 10.7454
NCC021 GDSC1; GDSC2 -5.3427 -1.8126 -7.8219 6.9817
KTCTL-195 GDSC1; GDSC2 -4.9492 5.9777 -7.0885 40.4745
RXF 393L GDSC1; GDSC2 -4.8908 3.668 -6.1435 38.8809
LB1047-RCC GDSC1; GDSC2 -4.424 1.9669 -9.0111 11.7452
BFTC-909 GDSC1; GDSC2 -3.701 10.9387 -7.9938 38.2386
769-P GDSC1; GDSC2 -3.4099 3.6175 -4.5304 31.0397
UO-31 GDSC1; GDSC2; CTRP2 -2.4249 7.02 -3.4822 39.6874
KMRC-20 GDSC1; GDSC2 -1.9661 13.0294 -7.3118 33.2636
786-O GDSC1; GDSC2; CTRP2 -1.8631 10.6017 -4.149 39.1165
NCC010 GDSC1; GDSC2 -0.8067 9.9023 -4.7032 25.2913
CAL-54 GDSC1; GDSC2; CTRP2 -0.4615 13.687 -3.9843 35.7174
SW156 GDSC1; GDSC2 -0.4559 2.5564 -7.2817 0.1892
TK-10 GDSC1; GDSC2 -0.3398 11.7064 -5.1575 25.4893
KTCTL-26A GDSC1; GDSC2 -0.0552 5.1 -8.028 1.5518
VMRC-RCW GDSC1; GDSC2 0.0918 3.7528 -7.4945 0.3514
Caki-2 CTRP2 0.4092 25.0654 -8.4915 45.9911
KMRC-1 GDSC1; GDSC2; CTRP2 2.3839 15.7376 -2.111 27.0435
SN12C GDSC1; GDSC2 2.7884 14.7236 -4.0104 16.9929
A-704 GDSC1; GDSC2 3.1404 13.8876 -3.323 14.4523
HA7-RCC GDSC1; GDSC2 3.3033 19.84 -6.1531 21.6476
OS-RC-2 GDSC1; GDSC2 4.31 13.6683 -2.3641 9.9057
ACHN GDSC1; GDSC2; CTRP2 4.4216 18.0345 -1.3515 22.1373
RCC10RGB GDSC1; GDSC2; CTRP2 6.3032 18.5021 0.0299 16.2385
TUHR14TKB CTRP2 7.7744 11.6957 4.4974 8.0209
VMRC-RCZ GDSC1; GDSC2; CTRP2 9.4413 27.9726 -2.2336 17.5868
A-498 GDSC1; GDSC2; CTRP2 9.9607 31.2095 -3.4421 19.3518
Caki-1 GDSC1; GDSC2; CTRP2 10.618 20.7555 2.061 6.4603
KMRC-2 CTRP2 12.2055 50.0922 -11.0794 31.4133
⏷ Show the Full List of 36 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 54 Cell Line(s) in Large Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
GP2d CTRP2 -11.558 14.4527 -15.974 69.5707
SW48 GDSC1; GDSC2 -9.1438 -6.4143 -9.1443 60.0106
SNU-175 GDSC2 -8.9882 -6.2192 -8.9888 59.1409
GP5d GDSC1; GDSC2 -8.2253 -5.8571 -8.2255 54.8892
HCT 116 GDSC1; GDSC2 -8.2168 -3.0343 -8.2896 54.6257
SK-CO-1 GDSC1; GDSC2 -7.9417 -1.4555 -8.1671 52.998
HT-29 GDSC1; GDSC2 -7.8492 -3.4259 -7.886 52.722
HCC2998 GDSC1; GDSC2 -7.7949 -3.8103 -7.8154 52.448
MDST8 GDSC1; GDSC2 -7.6614 1.5248 -8.4894 51.3699
RKO GDSC1; GDSC2 -7.6295 -2.9025 -7.688 51.5099
LoVo GDSC1; GDSC2 -6.8162 -3.5098 -6.8275 47.0239
SNU-283 GDSC2 -6.6606 -5.1441 -7.2124 6.7064
KM12 GDSC1; GDSC2 -6.6352 1.5697 -7.3818 46.6686
COLO205 GDSC1; GDSC2 -6.567 -1.5627 -6.6907 45.7867
NCI-H508 GDSC1; GDSC2 -6.1502 1.2087 -9.9451 20.8546
SNU-C5 GDSC1; GDSC2 -6.0341 4.2627 -7.5891 44.5539
SW948 GDSC1; GDSC2; CTRP2 -5.4857 0.061 -5.5376 51.5931
HT-55 GDSC1; GDSC2 -5.3735 1.3115 -5.9361 40.117
DiFi GDSC1; GDSC2 -5.334 0.7743 -5.761 39.6552
SW620 GDSC1; GDSC2 -5.0184 3.8954 -6.3623 39.6487
HT115 GDSC1; GDSC2 -4.7081 -1.0578 -4.7816 35.4112
SW626 GDSC1; GDSC2 -4.2406 4.3448 -5.6933 36.0565
CCK-81 GDSC1; GDSC2 -4.1882 -1.1268 -4.2317 32.4245
T84 GDSC1; GDSC2; CTRP2 -4.1436 1.7571 -4.2619 45.7597
HCT 15 GDSC1; GDSC2; CTRP2 -3.5589 2.9181 -3.7774 43.327
LS513 GDSC1; GDSC2 -3.479 2.4417 -4.1971 30.3476
SNU-C2B GDSC1; GDSC2 -3.4732 3.2109 -4.4513 31.0076
SNU-81 GDSC1; GDSC2 -1.8597 6.0272 -3.9012 25.4295
SNU-C4 CTRP2 -1.6519 2.8301 -1.7436 51.2109
COLO 320HSR GDSC1; GDSC2 -1.2197 4.6413 -2.6333 20.1134
CL-11 GDSC1; GDSC2 -0.3922 7.6609 -3.2252 20.2172
LS180 GDSC1; GDSC2 -0.2582 6.5477 -2.5608 17.8281
SNU-1040 GDSC2 -0.1183 21.2194 -9.6854 41.8113
HCC-56 CTRP2 -0.0294 11.2663 -2.4893 44.0825
LS411N GDSC1; GDSC2 0.0101 15.1613 -6.5565 27.931
SNU-C1 GDSC1; GDSC2; CTRP2 0.0329 7.8603 -1.0885 29.4645
CaR-1 GDSC1; GDSC2 0.1821 15.9265 -6.786 28.0708
SW1463 GDSC1; GDSC2 0.3888 17.1164 -7.1988 28.4872
NCI-H747 GDSC1; GDSC2; CTRP2 0.4745 13.0198 -2.7337 31.7985
SW837 GDSC1; GDSC2 0.721 8.8204 -2.7758 16.6517
CW-2 GDSC1; GDSC2 0.8155 6.6795 -1.629 12.6338
NCI-H716 GDSC1; GDSC2; CTRP2 1.0527 9.3396 -0.5572 26.1698
SNU-61 GDSC1; GDSC2 1.0723 8.9533 -2.5347 15.2386
HCT 8 CTRP2 1.1484 5.0859 0.9291 33.3286
SNU-407 GDSC1; GDSC2 1.1563 13.5612 -4.764 21.7122
LS123 GDSC1; GDSC2 1.3261 15.1911 -5.435 23.1032
C2BBe1 GDSC1; GDSC2; CTRP2 1.4769 17.5678 -3.858 31.7485
SW1417 GDSC1; GDSC2; CTRP2 1.5092 28.0951 -8.9562 37.4517
SW1116 GDSC1; GDSC2 1.6409 10.5624 -2.8572 15.3188
LS1034 GDSC1; GDSC2; CTRP2 2.3476 13.9353 -1.2873 25.3883
COLO 320 CTRP2 2.6597 15.2269 -1.602 34.6402
COLO 678 GDSC1; GDSC2; CTRP2 5.5723 22.5555 -2.6078 23.0762
SNU-503 CTRP2 8.6696 52.4669 -15.017 37.6973
RCM-1 [Human ESC] GDSC1; GDSC2; CTRP2 15.0708 38.4798 -3.409 14.5674
⏷ Show the Full List of 54 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Leukemia Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
MO-T GDSC1; GDSC2 3.0938 12.8675 -2.8535 13.0698
Cancer Drug Sensitivity Data Curated from 19 Cell Line(s) in Liver Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HLF CTRP2 -10.9548 21.7139 -18.2875 65.1523
SNU-398 GDSC1; GDSC2 -8.1778 -4.462 -8.1883 54.5776
HLE GDSC1; GDSC2 -7.2917 -3.9421 -7.3007 49.67
SNU-423 GDSC1; GDSC2; CTRP2 -3.6043 12.5909 -6.7876 45.6646
JHH-7 GDSC1; GDSC2 -3.5648 8.829 -6.8886 36.3181
JHH-4 GDSC1; GDSC2; CTRP2 -2.5336 4.2177 -2.889 39.0755
HuH-1 GDSC1; GDSC2 -2.4316 4.8525 -3.9802 27.0264
JHH-2 GDSC1; GDSC2; CTRP2 -2.1123 10.0627 -4.2052 39.8006
JHH-5 CTRP2 -0.9579 46.572 -20.3147 49.4247
PLC/PRF/5 CTRP2 0.2607 32.699 -12.3642 47.1493
JHH-1 GDSC1; GDSC2; CTRP2 1.1298 11.8123 -1.529 28.1674
Hep 3B2.1-7 GDSC1; GDSC2 1.2399 14.5112 -5.1679 22.5977
Hep-G2/C3A GDSC1; GDSC2 2.0414 10.3965 -2.4465 13.3384
SNU-387 GDSC1; GDSC2; CTRP2 2.5135 22.2389 -5.1556 31.8739
SNU-449 GDSC1; GDSC2; CTRP2 2.7369 9.7585 1.0216 19.1237
SK-HEP-1 GDSC1; GDSC2; CTRP2 3.9123 20.3704 -2.9648 26.1734
JHH-6 GDSC1; GDSC2; CTRP2 4.291 19.9168 -2.4022 24.5246
SNU-475 CTRP2 4.5119 16.9468 -0.7313 28.251
Huh-7 GDSC1; GDSC2 5.5394 17.2129 -3.2299 11.0704
⏷ Show the Full List of 19 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 203 Cell Line(s) in Lung Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
DV-90 CTRP2 -13.3858 4.247 -14.6979 80.212
HCC1438 CTRP2 -13.2181 6.8524 -15.2035 77.3213
NCI-H292 GDSC1; GDSC2 -10.7338 -6.2611 -11.1535 45.1945
NCI-H322 CTRP2 -10.6613 26.9216 -20.2639 62.9395
COR-L51 CTRP2 -10.6036 -0.9816 -10.795 85.3706
LK2 CTRP2 -10.4038 -9.6364 -10.4038 99.9624
HARA [Human squamous cell lung carcinoma] GDSC1; GDSC2 -10.1005 -5.7532 -10.1112 64.9392
DMS 273 GDSC1; GDSC2; CTRP2 -9.7686 8.8368 -12.0488 61.8285
HCC15 GDSC1; GDSC2 -9.5312 -4.8063 -9.5555 61.7582
NCI-H2171 GDSC2; CTRP2 -9.4505 5.8244 -10.8061 62.6772
NCI-H460 GDSC1; GDSC2 -9.3013 -6.059 -9.6489 31.6151
NCI-H1339 CTRP2 -9.1302 4.7887 -10.1908 74.9719
LUDLU-1 CTRP2 -8.9496 15.2691 -13.5151 65.8178
LK-2 GDSC1; GDSC2 -8.9167 -7.284 -8.9167 58.7604
IST-SL1 GDSC1; GDSC2 -8.8541 -6.5986 -9.015 26.2422
NCI-H2122 GDSC1; GDSC2 -8.8523 -6.7359 -8.8523 58.3981
NCI-H1437 GDSC1; GDSC2 -8.7325 -5.8807 -9.0851 26.0407
EMC-BAC-1 GDSC1; GDSC2 -8.7224 -4.1651 -9.734 29.2422
NCI-H2009 GDSC1; GDSC2 -8.6814 -3.1934 -10.1183 30.745
NCI-H1703 GDSC1; GDSC2; CTRP2 -8.662 -6.2093 -8.662 65.8501
A-549 GDSC1; GDSC2 -8.6095 -3.6647 -8.6575 56.7681
NCI-H1792 GDSC1; GDSC2 -8.5439 -5.4774 -8.5459 56.65
NCI-H2110 GDSC1; GDSC2; CTRP2 -8.5266 -4.3346 -8.5284 65.1082
NCI-H838 GDSC1; GDSC2; CTRP2 -8.5122 -5.0168 -8.5126 65.132
NCI-H1581 GDSC1; GDSC2 -8.395 -5.078 -8.399 55.8076
LOU-NH91 GDSC1; GDSC2 -8.3354 -3.5152 -8.3825 55.3177
SBC-5 GDSC1; GDSC2 -8.3193 -4.7104 -8.3271 55.3683
LXF 289 GDSC1; GDSC2 -8.2653 -1.7114 -8.4771 54.6221
NCI-H446 GDSC1; GDSC2 -8.074 -5.2137 -8.0755 54.0365
SBC-3 GDSC1; GDSC2 -8.0573 -5.4305 -8.058 53.947
NCI-H524 GDSC1; GDSC2 -8.0259 -6.1656 -8.0259 53.7761
EMC-BAC-2 GDSC1; GDSC2 -8.007 -2.5028 -8.1136 53.4668
RERF-LC-MS GDSC1; GDSC2; CTRP2 -7.9648 -3.2486 -7.9711 62.5505
HCC33 GDSC2 -7.9594 -5.2526 -8.4828 19.3214
PC-14 GDSC1; GDSC2 -7.8218 -4.4922 -7.8279 52.6195
LC-2/ad GDSC1; GDSC2 -7.7937 -5.4483 -8.2292 17.1724
HCC44 GDSC1; GDSC2 -7.7913 5.1557 -9.8048 51.5766
NCI-H1648 GDSC1; GDSC2 -7.7871 -3.9604 -8.8701 20.8367
NCI-H1651 GDSC1; GDSC2; CTRP2 -7.546 -3.9935 -7.5467 60.8271
NCI-H526 GDSC1; GDSC2 -7.497 -4.3416 -7.5022 50.8138
NCI-H1048 GDSC1; GDSC2 -7.4834 -3.0716 -7.5268 50.7239
NCI-H510A GDSC1; GDSC2 -7.4586 -4.0568 -8.5003 17.445
NCI-H3122 GDSC1; GDSC2 -7.4583 -3.4564 -7.4835 50.5914
SBC-1 GDSC1; GDSC2 -7.4128 -3.5061 -8.7174 18.5472
NCI-H2066 GDSC1; GDSC2 -7.3374 -2.5811 -9.0939 20.3996
EPLC-272H GDSC1; GDSC2 -7.2754 4.4416 -8.9918 49.7104
Calu-6 GDSC1; GDSC2 -7.238 -1.4342 -7.4188 49.4091
CAL-12T GDSC1; GDSC2 -7.2186 0.017 -10.2665 25.6701
NCI-H841 GDSC1; GDSC2; CTRP2 -7.1545 1.8214 -7.4652 57.9552
NCI-H748 GDSC2 -7.1012 -2.5831 -8.8748 18.3456
LCLC-103H GDSC1; GDSC2 -7.0632 -2.8096 -7.1071 48.4214
NCI-H1734 GDSC1; GDSC2 -6.961 -3.8184 -8.1393 13.4888
SHP-77 GDSC1; GDSC2 -6.8207 -4.3262 -6.8221 47.0351
COR-L279 GDSC1; GDSC2; CTRP2 -6.6887 1.0264 -6.8708 56.442
LB647-SCLC GDSC1; GDSC2 -6.6468 -4.9785 -7.2805 7.0847
NCI-H522 GDSC2; CTRP2 -6.5803 2.4083 -6.938 55.7192
NCI-H520 GDSC1; GDSC2; CTRP2 -6.5675 3.0435 -7.0315 55.527
NCI-H69 GDSC1; GDSC2 -6.5297 -3.7475 -7.7862 9.8876
NCI-H290 GDSC1; GDSC2 -6.5257 -1.9339 -8.688 15.3883
LCLC-97TM1 GDSC1; GDSC2 -6.5085 -0.6529 -6.7527 45.6094
NCI-H847 GDSC1; GDSC2 -6.4777 -5.2065 -7.0142 4.8579
NCI-H720 GDSC1; GDSC2 -6.4303 0.7662 -6.9531 45.4871
NCI-H1770 GDSC1; GDSC2 -6.388 -2.9845 -8.046 11.0837
NCI-H1355 GDSC1; GDSC2 -6.3751 2.179 -7.2713 45.5468
COR-L321 GDSC1; GDSC2 -6.3222 0.962 -9.9641 21.4536
NCI-H2795 GDSC1; GDSC2 -6.2032 2.7437 -7.257 44.8774
NCI-H1341 GDSC1; GDSC2; CTRP2 -6.1991 -3.0955 -6.1996 54.8227
Lu-134-A GDSC1; GDSC2 -6.1908 -3.9617 -7.3946 6.4196
NCI-H1155 GDSC1; GDSC2 -6.1856 -1.6688 -6.2773 43.6543
NCI-H23 GDSC1; GDSC2; CTRP2 -6.1583 -1.5709 -6.1704 54.5981
NCI-H1436 GDSC1; GDSC2 -6.1511 -3.2148 -7.7355 8.459
COR-L303 GDSC2 -6.1423 3.0031 -10.8356 24.5606
NCI-H64 GDSC1; GDSC2 -6.024 -1.0473 -8.7153 14.0656
NCI-H2030 GDSC1; GDSC2 -5.8407 -1.0231 -8.5817 12.7819
NCI-H1975 GDSC1; GDSC2 -5.659 5.9053 -7.8105 43.4919
HCC4006 CTRP2 -5.636 57.8019 -30.1139 53.589
HCC366 GDSC1; GDSC2 -5.6085 3.8922 -6.9977 42.4822
NCI-H1568 GDSC1; GDSC2; CTRP2 -5.5416 2.4906 -5.8367 51.7124
NCI-H1836 GDSC1; GDSC2 -5.3691 0.7276 -9.0875 14.3889
NCI-H82 GDSC1; GDSC2 -5.2896 0.5722 -5.6672 39.3193
NCI-H358 GDSC1; GDSC2 -5.1889 3.812 -6.5164 40.438
NCI-H1688 GDSC1; GDSC2 -4.9704 2.0485 -9.4412 15.2362
NCI-H1623 GDSC1; GDSC2; CTRP2 -4.9642 3.2373 -5.3361 49.3638
NCI-H1944 GDSC1; GDSC2; CTRP2 -4.6911 5.039 -5.4131 48.3605
NCI-H835 GDSC1; GDSC2 -4.6834 1.0313 -8.7388 10.8441
NCI-H209 GDSC1; GDSC2 -4.4819 3.7301 -5.7247 36.8409
UMC-11 GDSC1; GDSC2 -4.2936 2.3624 -5.0585 34.8471
DMS 114 GDSC1; GDSC2; CTRP2 -4.279 6.5017 -5.3499 46.9335
NCI-H1573 GDSC1; GDSC2 -4.2339 9.0886 -12.3638 24.7845
NCI-H211 GDSC1; GDSC2 -3.995 4.142 -5.3537 34.6333
NCI-H1666 GDSC1; GDSC2 -3.7721 6.2179 -5.9533 35.2295
Ms-1 GDSC1; GDSC2 -3.7599 3.0241 -4.696 32.4269
NCI-H1299 GDSC1; GDSC2 -3.6326 4.2297 -4.9999 32.8081
VMRC-LCD GDSC1; GDSC2; CTRP2 -3.6264 9.1269 -5.4873 45.0246
NCI-H322M GDSC1; GDSC2 -3.4376 2.8605 -4.291 30.4873
SK-MES-1 GDSC1; GDSC2; CTRP2 -3.3682 15.2371 -7.6498 45.474
LC-1/sq GDSC1; GDSC2 -3.2866 6.4276 -5.5392 33.0807
NCI-H2081 GDSC1; GDSC2; CTRP2 -3.1402 7.4203 -4.3859 42.7452
NCI-H2023 GDSC1; GDSC2 -3.0655 11.4047 -7.5877 36.1592
NCI-H596 GDSC1; GDSC2 -2.9587 9.1517 -6.4294 34.0056
COLO 668 GDSC1; GDSC2; CTRP2 -2.4711 3.1914 -2.6538 38.4947
Lu-139 GDSC1; GDSC2 -2.4245 7.1554 -4.9809 29.6254
NCI-H2818 GDSC1; GDSC2 -2.3448 6.5536 -4.6294 28.5566
PaCa-3 GDSC1; GDSC2 -2.2589 10.3437 -11.5601 18.2636
NCI-H810 GDSC1; GDSC2; CTRP2 -2.1659 15.7493 -6.6381 42.1865
NCI-H1755 GDSC1; GDSC2 -1.7522 12.5084 -6.8577 32.0199
COR-L88 GDSC1; GDSC2 -1.5917 8.4458 -10.235 12.1278
SW1271 GDSC1; GDSC2 -1.3468 10.3505 -5.4296 28.2173
T3M-10 CTRP2 -1.2713 56.5284 -25.5265 49.8212
RERF-LC-Sq1 GDSC1; GDSC2 -1.1075 10.606 -5.3276 27.4682
NCI-H2196 GDSC2; CTRP2 -1.0894 9.9685 -3.0782 35.7612
COR-L23 GDSC1; GDSC2 -1.0816 13.8539 -6.8924 30.6916
NCI-H2291 GDSC1; GDSC2 -1.0067 7.3028 -9.3807 7.6623
NCI-H1993 GDSC1; GDSC2 -0.9888 8.145 -4.0269 23.8411
NCI-H2228 GDSC1; GDSC2 -0.9254 13.2057 -6.4304 29.4883
CPC-N GDSC1; GDSC2 -0.8916 11.1181 -5.3755 27.1292
NCI-H647 GDSC1; GDSC2; CTRP2 -0.8201 21.0132 -7.7193 40.3018
NCI-H146 GDSC1; GDSC2; CTRP2 -0.7477 7.2099 -1.7162 32.5073
NCI-H1876 GDSC1; GDSC2 -0.7128 6.2451 -2.8567 19.7222
NCI-H1963 GDSC1; GDSC2 -0.68 6.7012 -3.0404 20.2343
NCI-H2369 GDSC1; GDSC2 -0.6745 11.253 -5.2407 26.3627
NCI-H1105 GDSC1; GDSC2; CTRP2 -0.6594 11.3851 -3.197 34.974
NCI-H1915 GDSC1; GDSC2; CTRP2 -0.6239 14.9958 -4.7341 37.0409
NCI-H2347 GDSC1; GDSC2 -0.588 6.9665 -9.015 5.6064
NCI-H1781 GDSC1; GDSC2 -0.5438 10.0203 -4.5159 24.2575
ChaGo-K-1 GDSC1; GDSC2; CTRP2 -0.4755 18.1992 -6.0581 38.2076
A-427 GDSC1; GDSC2 -0.4528 14.9817 -6.8792 29.4339
NCI-H2444 GDSC1; GDSC2 -0.3911 5.1311 -8.1799 2.2307
Lu-65 GDSC1; GDSC2; CTRP2 -0.3657 13.8681 -3.9669 35.4906
NCI-H2085 GDSC1; GDSC2 -0.3471 12.4582 -5.5353 26.4043
NCI-H2804 GDSC1; GDSC2 -0.3451 14.3475 -6.4684 28.4236
COR-L32 GDSC2 -0.3228 3.3766 -7.5127 0.471
HCC78 GDSC1; GDSC2 -0.2433 14.1119 -6.2606 27.8013
BEN GDSC1; GDSC2 -0.1112 12.7584 -11.3173 13.8784
NCI-H740 GDSC2 -0.0948 6.8012 -8.706 3.8771
NCI-H2087 GDSC1; GDSC2 -0.0556 11.5764 -4.8361 24.1265
NCI-H2172 GDSC1; GDSC2 0.1023 3.4041 -7.3739 0.208
NCI-H1304 GDSC1 0.1319 2.2819 -7.0009 0.0167
RERF-LC-KJ GDSC1; GDSC2 0.216 15.7674 -6.6771 27.7943
NCI-H187 GDSC1 0.2217 5.33 -8.002 1.6356
NCI-H1838 GDSC1; GDSC2 0.2578 4.9298 -7.8434 0.9365
NCI-H2810 GDSC1; GDSC2 0.2736 16.0305 -6.7578 27.8496
IST-SL2 GDSC1; GDSC2 0.3919 7.3736 -2.3552 15.8799
NCI-H1693 GDSC1; GDSC2; CTRP2 0.3923 9.9719 -1.5101 29.6094
NCI-H2029 GDSC1; GDSC2; CTRP2 0.4048 11.1977 -2.0086 30.5913
EBC-1 GDSC1; GDSC2 0.4241 13.9581 -5.5938 25.0763
NCI-H2731 GDSC1; GDSC2 0.4505 15.82 -6.4988 27.0096
COR-L95 GDSC1; GDSC2; CTRP2 0.5019 14.3835 -3.3223 32.7406
NCI-H2595 GDSC1; GDSC2 0.5071 12.1638 -4.6276 22.5176
COR-L311 GDSC2 0.6406 17.0158 -6.9309 27.5356
SK-LU-1 GDSC1; GDSC2 0.7391 15.0462 -5.8629 25.1241
Lu-99A GDSC1; GDSC2 0.7465 12.2188 -4.4459 21.5923
NCI-H2461 GDSC1; GDSC2 0.7599 14.0833 -5.3644 23.9232
NCI-H3255 GDSC1; GDSC2 0.7999 18.7673 -7.6689 28.6261
DMS 53 GDSC1; GDSC2; CTRP2 0.8299 9.6324 -0.9108 27.4197
NCI-H250 GDSC2 0.8699 13.3016 -4.8794 22.5172
NCI-H2227 GDSC1; GDSC2 0.8707 14.512 -5.483 24.0102
Lu-135 GDSC1; GDSC2 0.9463 12.3982 -4.3627 21.006
NCI-H1694 GDSC1; GDSC2; CTRP2 1.1091 12.6386 -1.919 29.0068
COR-L47 CTRP2 1.3184 30.7669 -10.4468 44.9641
Calu-3 GDSC1; GDSC2 1.6275 9.1037 -2.139 12.9797
NCI-H2373 GDSC1; GDSC2 1.849 15.6392 -5.2234 21.7109
NCI-H2141 GDSC1; GDSC2; CTRP2 2.1102 14.2744 -1.679 26.6478
NCI-H345 GDSC1; GDSC2 2.1287 3.7196 0.9297 1.5662
NCI-H441 GDSC1; GDSC2 2.2346 15.5492 -4.8634 20.1744
Lu-165 GDSC1; GDSC2 2.2716 7.551 -0.8469 7.5289
NCI-H196 GDSC1; GDSC2 2.6891 5.2225 0.5834 2.0956
NCI-H513 GDSC1; GDSC2 2.8126 13.5908 -3.4281 15.2515
NCI-H2135 GDSC1; GDSC2 2.8327 12.6605 -2.9505 13.7536
NCI-H2803 GDSC1; GDSC2 2.9408 9.4199 -1.268 8.0512
NCI-H2869 GDSC1; GDSC2 3.236 19.3501 -5.9619 21.3149
DMS 79 GDSC1; GDSC2 3.4815 12.9597 -2.6097 11.7574
SW1573 GDSC1; GDSC2 3.5842 15.8777 -3.9714 15.7186
HCC827 GDSC1; GDSC2 3.6118 16.3895 -4.2035 16.33
IA-LM GDSC1; GDSC2; CTRP2 3.7546 12.8455 0.5876 18.5242
NCI-H650 GDSC1; GDSC2 3.8072 21.9037 -6.787 22.2918
HOP-62 GDSC1; GDSC2; CTRP2 3.8185 28.8784 -7.2767 32.5408
NCI-H2170 GDSC1; GDSC2; CTRP2 3.8718 22.3955 -4.0055 28.0385
ABC-1 GDSC1; GDSC2 3.878 17.538 -4.5705 16.9532
DMS 454 CTRP2 3.9995 33.1191 -9.2326 40.0958
NCI-H2405 GDSC1; GDSC2 4.1874 13.58 -2.4065 10.1917
NCI-H1092 GDSC1; GDSC2; CTRP2 4.2068 16.6413 -0.8538 21.3435
NCI-H2591 GDSC1; GDSC2 4.2479 7.2822 0.5308 1.0489
NCI-H1869 GDSC1; GDSC2; CTRP2 4.2554 23.6288 -4.2798 27.9095
NCI-H1435 GDSC1; GDSC2 4.4608 6.1208 1.0529 0.0929
NCI-H661 GDSC1; GDSC2 4.4621 6.8666 0.7877 0.4265
COR-L105 GDSC1; GDSC2; CTRP2 4.819 19.427 -1.6937 22.2865
EKVX GDSC1; GDSC2; CTRP2 4.934 20.6733 -2.2149 23.2001
NCI-H1793 GDSC1; GDSC2; CTRP2 5.1079 27.8227 -5.6347 28.7288
NCI-H2342 GDSC1; GDSC2; CTRP2 5.2958 15.5026 0.6779 15.9634
NCI-H2722 GDSC1; GDSC2 5.701 20.4892 -4.6955 14.9129
NCI-H1395 CTRP2 5.7014 18.9192 -0.681 25.5832
NCI-H226 GDSC1; GDSC2 5.7259 20.2933 -4.5834 14.5917
RERF-LC-Ad2 CTRP2 6.0888 37.1943 -9.4935 37.2525
NCI-H1650 GDSC1; GDSC2 7.5799 22.0459 -4.1852 11.4866
NCI-H727 GDSC1; GDSC2 8.4936 25.5773 -5.2582 13.226
LC-1/sq-SF CTRP2 9.6113 63.7499 -19.8924 39.0319
Calu-1 CTRP2 10.0015 38.4783 -7.0044 29.6952
HOP-92 GDSC1; GDSC2; CTRP2 10.9571 26.0934 -0.2404 11.7181
HCC2935 CTRP2 11.3977 39.575 -6.4956 27.3488
KNS-62 GDSC1; GDSC2; CTRP2 14.7872 58.4066 -13.256 27.3078
NCI-H1563 GDSC1; GDSC2; CTRP2 15.6984 44.0431 -5.6367 17.7309
Hs 888.Lu CTRP2 2.4332 30.6496 -9.3836 42.6797
⏷ Show the Full List of 203 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Lymphoma Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CBTCi002-A GDSC1; GDSC2 1.1906 9.0959 -2.504 14.9318
Cancer Drug Sensitivity Data Curated from 3 Cell Line(s) in Thigh Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SYO-1 CTRP2 -13.5745 19.284 -20.0182 68.8748
H-STS CTRP2 -10.144 -1.7748 -10.2512 86.3925
P-STS CTRP2 0.3619 33.049 -12.4436 47.004
Cancer Drug Sensitivity Data Curated from 36 Cell Line(s) in Ovary Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
2004 CTRP2 -6.1448 69.0321 -36.1069 53.4037
Caov-3 GDSC2 -9.215 -4.8892 -9.9602 32.5863
DOV13 GDSC1; GDSC2 -8.6698 -4.3972 -8.6896 57.2205
OVCAR-8 GDSC1; GDSC2 -8.363 -5.8936 -8.3634 55.6582
OC 314 GDSC1; GDSC2; CTRP2 -8.2199 -5.616 -8.2199 63.8697
TOV-112D GDSC1; GDSC2; CTRP2 -7.8194 -4.1251 -7.8202 62.0353
A2780 GDSC1; GDSC2 -7.1222 -3.7741 -7.1322 48.7272
JHOS-4 GDSC1; GDSC2 -7.0247 0.5431 -10.3563 25.3913
OVCAR-3 GDSC1; GDSC2 -6.1653 -3.1999 -6.1739 43.3853
TYK-nu GDSC1; GDSC2 -5.611 0.7915 -6.0666 41.1758
JHOM-1 CTRP2 -4.826 30.3076 -16.0163 55.149
COV434 CTRP2 -4.6776 82.2786 -41.3395 52.025
FU-OV-1 GDSC1; GDSC2 -4.1399 4.396 -9.9892 15.9178
IGROV-1 GDSC1; GDSC2 -3.8841 9.3718 -7.4565 37.9886
RMG-I GDSC1; GDSC2 -3.8409 2.5356 -8.8931 9.9243
ES-2 GDSC1; GDSC2 -3.7414 4.7368 -5.3136 33.8262
OVTOKO GDSC1; GDSC2 -2.63 4.6034 -4.0852 27.8131
OVK18 GDSC1; GDSC2 -1.3802 8.959 -4.7925 26.7461
COV362 CTRP2 -0.9805 119.4061 -56.592 49.7812
SK-OV-3 GDSC1; GDSC2 -0.8296 10.9462 -5.2339 26.6645
OVCAR-5 GDSC1; GDSC2; CTRP2 -0.8254 32.6537 -13.3443 43.2898
Caov-4 GDSC1; GDSC2 -0.2354 2.9684 -7.3438 0.2232
COV644 CTRP2 -0.2158 165.4935 -78.9552 49.5877
OAW42 GDSC1; GDSC2; CTRP2 -0.0412 8.266 -1.3131 30.1086
OVKATE GDSC1; GDSC2 0.1477 5.7751 -8.1976 1.9354
OV7 CTRP2 0.4708 41.0443 -16.2929 47.4227
Kuramochi GDSC1; GDSC2 1.3627 15.8613 -5.7393 23.7584
TOV-21G GDSC1; GDSC2; CTRP2 1.8437 21.4552 -5.3912 33.2802
OVCAR-4 GDSC1; GDSC2 3.9403 18.7012 -5.0983 18.2332
EFO-27 GDSC1; GDSC2; CTRP2 4.1378 24.7282 -4.9303 29.0766
OVISE GDSC1; GDSC2 4.6861 20.6242 -5.4901 18.1851
EFO-21 GDSC1; GDSC2; CTRP2 4.9891 25.8807 -4.7663 27.624
OAW28 GDSC1; GDSC2; CTRP2 5.5091 20.6884 -1.7283 21.3731
OV56 GDSC1; GDSC2; CTRP2 5.9072 20.4687 -1.2824 19.8547
OV-90 GDSC1; GDSC2; CTRP2 6.4405 20.8143 -1.0131 18.5376
JHOS-2 GDSC1; GDSC2; CTRP2 8.5598 28.8809 -3.3513 20.7275
⏷ Show the Full List of 36 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Clivus Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
U-CH1 CTRP2 5.212 10.1532 3.2608 13.3853
Cancer Drug Sensitivity Data Curated from 30 Cell Line(s) in Soft Tissue Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
Aska-SS CTRP2 10.1351 45.6269 -10.4496 33.0544
TE 617.T CTRP2 -14.4416 9.0962 -17.2148 76.2994
EW-8 GDSC1; GDSC2 -10.4237 -8.139 -10.4237 67.1722
BT-16 CTRP2 -9.594 22.0129 -17.0084 63.4883
KYM-1 GDSC1; GDSC2; CTRP2 -9.0298 -0.4265 -9.193 65.3193
Hs 633.T GDSC1; GDSC2 -8.3024 -5.1564 -8.8845 23.0353
G-401 GDSC1; GDSC2; CTRP2 -8.2292 6.9693 -9.7949 59.2105
STS-0421 GDSC1; GDSC2 -8.1025 -3.6193 -9.3419 24.6497
SW982 GDSC1; GDSC2; CTRP2 -7.7117 0.36 -7.8815 60.4632
Rh41 GDSC1; GDSC2 -7.6522 -2.6855 -7.7269 51.6218
TTC-709 CTRP2 -7.4165 114.0765 -59.5624 52.6861
GCT GDSC1; GDSC2; CTRP2 -6.5562 7.9328 -8.2656 54.4201
HT-1080 GDSC1; GDSC2; CTRP2 -6.4713 2.7258 -6.8724 55.2495
MES-SA GDSC1; GDSC2 -5.8117 0.3583 -6.1884 42.104
Hs 729.T CTRP2 -5.5572 48.1607 -25.3214 54.147
MFH-ino GDSC1; GDSC2 -5.4779 0.6894 -9.1514 15.0138
SK-LMS-1 GDSC1; GDSC2; CTRP2 -5.2522 17.2059 -10.4464 50.2918
Rh18 GDSC1 -4.9653 0.1493 -8.5085 12.3895
RKN GDSC1; GDSC2 -4.4846 2.3465 -5.2616 35.8845
TE 441.T GDSC2; CTRP2 -4.1052 14.3791 -8.0512 47.3596
G-402 GDSC1; GDSC2; CTRP2 -2.1211 18.0942 -7.6475 42.7652
RD GDSC1; GDSC2; CTRP2 -1.3839 12.2852 -4.331 38.2075
SW872 GDSC1; GDSC2 -0.9837 7.7893 -3.852 23.3299
A-204 GDSC1; GDSC2; CTRP2 -0.0764 18.1969 -5.6648 37.0273
BT-12 CTRP2 -0.0397 4397.0769 -2194.544 49.9822
Rh30 GDSC1; GDSC2 0.6927 29.9577 -13.3516 35.8281
VA-ES-BJ GDSC1; GDSC2 1.7314 20.325 -7.6633 27.0917
Tm87-16 CTRP2 5.4122 66.1309 -24.5273 43.8513
SW684 GDSC1; GDSC2 6.3409 27.4577 -7.6338 20.7205
SK-UT-1 GDSC1; GDSC2; CTRP2 8.5938 35.7975 -6.7646 26.0407
⏷ Show the Full List of 30 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Pleura Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
NCI-H2452 GDSC1; GDSC2 -8.1691 -1.8231 -10.2495 29.1219
NCI-H28 GDSC1; GDSC2 -0.9665 10.4825 -5.1353 26.7109
MPP 89 GDSC1; GDSC2; CTRP2 -0.7498 13.0605 -4.0051 36.3655
MSTO-211H GDSC1; GDSC2 0.7464 11.2206 -3.9483 20.1991
IST-Mes1 GDSC1; GDSC2 2.7072 15.9917 -4.7058 19.0235
NCI-H2052 GDSC1; GDSC2 4.7237 16.5452 -3.4683 12.7483
JL-1 CTRP2 7.502 30.9256 -5.2034 30.8037
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 7 Cell Line(s) in Prostate Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
LNCaP clone FGC GDSC1; GDSC2; CTRP2 -6.6811 11.8321 -9.7634 54.0443
DU145 GDSC1; GDSC2; CTRP2 -5.9861 36.728 -20.1965 51.0825
PC-3 GDSC1; GDSC2 -3.8281 3.3867 -4.8968 33.1115
22Rv1 GDSC1; GDSC2 -3.4743 5.4359 -5.3149 33.094
VCaP GDSC1; GDSC2; CTRP2 -2.639 38.8785 -18.0719 46.8124
PaCa-3 CTRP2 3.496 29.0947 -7.6677 39.8547
NCI-H660 GDSC2; CTRP2 6.5834 15.5725 1.7217 11.4632
⏷ Show the Full List of 7 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Salivary Gland Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
A-253 GDSC1; GDSC2; CTRP2 12.1333 33.6444 -3.0696 16.4996
Cancer Drug Sensitivity Data Curated from 69 Cell Line(s) in Skin Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
CJM [Human melanoma] CTRP2 -12.0071 1.7202 -12.666 82.3122
A2058 GDSC1; GDSC2 -10.1879 -7.8489 -10.188 65.8545
A-431 GDSC1; GDSC2 -9.3792 -3.601 -10.6566 36.018
DJM-1 GDSC1; GDSC2 -8.9769 -4.0721 -10.0383 31.764
RPMI-7951 GDSC1; GDSC2 -8.9623 -3.2889 -9.0477 58.4337
A-375 GDSC1; GDSC2 -8.8712 -6.5163 -8.8714 58.5007
IPC-298 GDSC1; GDSC2 -8.3538 -4.6914 -9.1279 24.5785
A-388 GDSC1; GDSC2 -8.2801 -4.0855 -9.3122 25.2339
CHL-1 GDSC1; GDSC2 -7.9439 -2.1526 -8.0821 53.0998
G-mel GDSC1; GDSC2 -7.9235 4.0158 -9.5445 52.1653
MZ-MEL-2 GDSC1; GDSC2 -7.4489 -2.2171 -9.3755 22.3035
SK-MEL-28 GDSC1; GDSC2 -7.4426 -2.853 -9.0604 20.596
IST-MEL1 GDSC1; GDSC2 -7.2046 -0.9917 -9.7542 23.3211
A101D GDSC1; GDSC2 -6.9849 -0.2109 -7.3455 48.1657
CP50-MEL-B GDSC1; GDSC2 -6.8633 -1.5529 -9.1714 19.1928
SK-MEL-30 GDSC1; GDSC2 -6.715 -0.585 -9.5242 20.5559
IGR-37 GDSC1; GDSC2; CTRP2 -6.2976 0.341 -6.3976 55.0064
COLO 783 GDSC1; GDSC2 -6.2638 -4.1805 -7.3446 6.3076
451Lu GDSC1; GDSC2 -6.2302 -0.4366 -9.1885 17.3076
Hs 938.T GDSC1; GDSC2 -6.2244 -1.1234 -8.8403 15.3604
Mel Ho GDSC1; GDSC2 -6.2215 -0.7917 -9.0037 16.2714
WM1552C GDSC1; GDSC2 -6.1071 -0.5117 -6.3441 43.459
SK-MEL-31 GDSC1; GDSC2 -5.4518 3.8706 -10.7124 22.1802
WM983B CTRP2 -5.3453 20.6191 -12.0447 57.8885
MMAc-SF GDSC1; GDSC2 -5.2503 3.4828 -10.3624 20.2231
Hs 294T CTRP2 -5.0377 22.068 -12.3878 56.9886
IGR-39 CTRP2 -4.8632 1.4496 -4.9894 68.9785
WM88 CTRP2 -4.3372 25.546 -13.2955 55.1396
COLO 792 GDSC1; GDSC2 -4.2994 3.7328 -5.5292 35.8976
M14 GDSC1; GDSC2 -4.1516 8.7417 -7.4436 38.6743
G-361 GDSC1; GDSC2 -4.1391 3.2773 -5.194 34.6995
WM793 GDSC1; GDSC2 -3.7592 8.8977 -7.1158 37.1735
LB2518-MEL GDSC1; GDSC2 -1.8197 9.3375 -10.7929 14.7139
LOX-IMVI GDSC1; GDSC2; CTRP2 -1.6178 29.6772 -12.6383 44.1726
WM35 GDSC1; GDSC2 -0.928 18.5145 -9.0555 33.8085
HMV-II GDSC1; GDSC2 -0.6376 14.5094 -6.8116 29.6617
LB373-MEL-D GDSC1; GDSC2 -0.5813 10.9458 -10.7704 12.6295
VMRC-MELG GDSC1; GDSC2 -0.3345 7.216 -8.9923 5.2338
WM115 GDSC1; GDSC2; CTRP2 -0.2827 14.3234 -4.0862 35.4844
CP66-MEL GDSC1; GDSC2 -0.2077 9.7496 -4.0731 22.3646
SK-MEL-1 GDSC1; GDSC2 0.01 4.1636 -7.6651 0.651
IGR-1 GDSC1; GDSC2; CTRP2 0.0564 21.2103 -6.9656 38.0923
MZ-MEL-7 GDSC1; GDSC2 0.0891 3.0093 -7.2485 0.1067
SK-MEL-5 GDSC1; GDSC2 0.279 13.5253 -5.5057 25.1381
COLO 829 GDSC1; GDSC2; CTRP2 0.6361 12.7423 -2.4454 30.9524
SK-MEL-24 GDSC1; GDSC2; CTRP2 0.7811 15.398 -3.512 32.4998
COLO 800 GDSC1; GDSC2; CTRP2 0.8905 37.2213 -14.0231 41.326
COLO 679 GDSC1; GDSC2 1.1532 13.5267 -4.7494 21.6793
GAK GDSC1; GDSC2 1.2019 18.1315 -7.0097 26.7288
HT-144 GDSC1; GDSC2; CTRP2 1.5726 23.1249 -6.4589 34.9986
SH-4 GDSC1; GDSC2 2.317 18.5721 -6.3066 23.4757
Hs 934.T CTRP2 2.7738 64.7272 -26.0652 46.2744
MeWo GDSC1; GDSC2; CTRP2 3.8525 18.2754 -1.9817 24.3537
Mel JuSo GDSC1; GDSC2 4.0731 16.4009 -3.8656 14.7425
SK-MEL-2 GDSC1; GDSC2; CTRP2 5.199 12.5489 2.0633 12.3708
K029AX CTRP2 5.7293 56.367 -19.3799 42.3291
Hs 940.T GDSC1; GDSC2; CTRP2 5.8933 22.3127 -2.216 21.8578
RVH-421 GDSC1; GDSC2; CTRP2 6.0944 17.5872 0.3146 15.8013
UACC-257 GDSC1; GDSC2; CTRP2 6.3659 19.9334 -0.634 17.759
WM266-4 CTRP2 7.0181 27.5021 -3.8842 29.6092
Hs 895.T CTRP2 7.3311 28.4077 -4.0839 29.4207
Hs 688(A).T CTRP2 7.4695 20.2023 0.1152 20.1037
WM278 GDSC1; GDSC2 8.0332 28.2834 -6.8478 17.2388
Malme-3M CTRP2 8.4118 11.5687 4.9165 1.685
Hs 839.T CTRP2 9.8005 22.3984 0.7465 14.5578
UACC-62 GDSC1; GDSC2; CTRP2 10.5756 26.2113 -0.5582 12.8083
WT2-iPS GDSC1; GDSC2; CTRP2 11.1041 35.1701 -4.5471 20.0988
SK-MEL-3 GDSC1; GDSC2; CTRP2 12.7997 42.9061 -7.1048 22.3135
EquiPSC Line K2 GDSC1; GDSC2 -5.678 -1.724 -8.1088 9.5245
⏷ Show the Full List of 69 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 1 Cell Line(s) in Small Intestine Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuTu 80 GDSC1; GDSC2 -9.733 -6.907 -9.7334 63.2855
Cancer Drug Sensitivity Data Curated from 38 Cell Line(s) in Stomach Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
HuG1-N CTRP2 -12.5199 34.3076 -25.4806 62.5681
SNU-601 CTRP2 -11.6389 39.3536 -26.9405 60.703
NCC-StC-K140 CTRP2 -11.0576 5.1072 -12.3722 77.0755
SNU-16 GDSC1; GDSC2; CTRP2 -9.7613 -8.6522 -9.7613 70.7781
SK-GT-2 GDSC1; GDSC2 -8.8273 -3.6847 -8.8814 57.8827
HSC-39 GDSC1; GDSC2 -8.4133 -6.4957 -8.5593 21.7495
AGS GDSC1; GDSC2 -7.6943 1.1856 -8.4355 51.5412
NUGC-3 GDSC1; GDSC2 -7.6443 -1.8177 -7.8028 51.5319
TMK-1 GDSC1; GDSC2 -7.5882 -4.3448 -8.4948 17.9032
23132/87 GDSC1; GDSC2 -7.4409 -5.0008 -7.4416 50.503
RF-48 GDSC1; GDSC2 -7.2705 -3.5698 -7.2879 49.554
TGBC11TKB GDSC1; GDSC2 -7.2166 -5.1884 -7.7377 11.9566
SH-10-TC CTRP2 -7.1029 8.3424 -8.9912 67.6347
IM95 GDSC1; GDSC2; CTRP2 -6.6584 -3.8757 -6.6585 56.8807
Fu97 GDSC1; GDSC2 -6.4284 3.6353 -11.3895 27.3433
SNU-5 GDSC1; GDSC2 -5.9672 -1.2922 -6.0861 42.5018
MKN1 GDSC1; GDSC2 -5.8285 0.1479 -6.1634 42.1249
MKN28 GDSC1; GDSC2 -4.9049 5.8979 -7.0095 40.2356
SNU-216 CTRP2 -4.0256 35.6336 -17.7984 53.4966
RERF-GC-1B GDSC1; GDSC2 -3.62 8.2239 -6.6719 36.1069
MKN45 GDSC1; GDSC2 -3.3902 12.9063 -8.6145 38.258
NCI-N87 GDSC1; GDSC2 -2.5727 10.1362 -6.5082 33.2225
ECC12 GDSC2 -1.0211 7.9554 -9.6768 8.9371
SCH GDSC1; GDSC2 -0.8881 12.8311 -11.8371 16.8142
GCIY GDSC1; GDSC2 -0.7506 7.6926 -3.5816 22.0418
ECC10 GDSC1; GDSC2 -0.5293 15.7584 -7.3326 30.409
Hs 746.T GDSC1; GDSC2; CTRP2 -0.4698 14.8509 -4.5129 36.443
HGC-27 GDSC1; GDSC2; CTRP2 -0.0932 700.6138 -346.3681 49.6059
OCUM-1 GDSC1; GDSC2 1.4318 17.6485 -6.5748 25.4722
NUGC-4 GDSC1; GDSC2 1.6738 11.9787 -3.5381 17.3786
SNU-1 GDSC1; GDSC2; CTRP2 1.8692 23.9059 -6.5666 34.6393
KATO III GDSC1; GDSC2; CTRP2 2.2428 15.5442 -2.1538 27.376
LMSU CTRP2 7.0191 34.7605 -7.5097 34.2276
MKN74 CTRP2 7.5117 28.658 -4.0641 29.1024
MKN7 GDSC1; GDSC2; CTRP2 8.7766 29.0301 -3.2584 20.3097
KE-39 CTRP2 13.9632 44.2278 -6.9181 25.063
SNG-M GDSC1; GDSC2 -8.6972 -6.0445 -8.6977 57.5215
SNU-685 CTRP2 0.5203 18.6696 -5.3065 44.4074
⏷ Show the Full List of 38 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 17 Cell Line(s) in Thyroid Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SW579 CTRP2 -10.907 4.1149 -11.9662 78.1026
CGTH-W-1 GDSC1; GDSC2 -9.58 -6.8927 -9.7395 33.4706
KMH-2 GDSC1; GDSC2 -8.967 -5.1393 -9.6 29.7472
IHH-4 GDSC1; GDSC2 -8.8662 -4.1411 -8.8992 58.195
CAL-62 GDSC1; GDSC2 -8.6239 -2.0426 -8.8159 56.418
K5 GDSC1; GDSC2 -7.5597 0.7709 -8.185 50.9658
HTC-C3 GDSC1; GDSC2 -7.0563 -2.8417 -7.0982 48.382
ML-1 [Human leukemia] GDSC1; GDSC2 -6.2184 -1.3104 -8.742 14.7784
8305C GDSC1; GDSC2 -5.278 3.3942 -6.4667 40.6584
B-CPAP GDSC1; GDSC2 -4.4382 7.2049 -7.0653 38.9425
BHT-101 GDSC1; GDSC2 -1.6519 10.8972 -5.983 30.0988
TT2609-C02 GDSC1; GDSC2; CTRP2 -1.1085 25.6078 -10.1908 42.3408
ASH-3 GDSC1; GDSC2 -0.9748 13.5384 -6.6394 29.9985
TT GDSC1; GDSC2 -0.5266 4.6909 -8.0691 1.9591
8505C GDSC1; GDSC2 0.8505 21.5854 -9.0337 30.7364
WRO GDSC1; GDSC2 1.9962 14.9571 -4.7616 20.2923
FTC-133 GDSC1; GDSC2; CTRP2 2.2548 33.9737 -11.1918 38.0513
⏷ Show the Full List of 17 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 48 Cell Line(s) in Upper Aerodigestive Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
PE/CA-PJ34 (clone C12) CTRP2 -19.1058 7.8028 -21.9024 80.2697
BICR 6 CTRP2 -15.7935 11.6265 -19.5162 75.3648
PE/CA-PJ49 CTRP2 -14.4584 -2.2834 -14.7258 89.2501
PCI-06A GDSC1; GDSC2 -12.1375 -10.7165 -12.1377 58.35
JHU-011 GDSC1; GDSC2 -10.8567 -7.0152 -11.1002 46.0028
KON GDSC1; GDSC2 -10.7725 -6.9041 -11.0333 45.2648
KOSC-2 GDSC1; GDSC2 -10.7532 -6.0326 -11.2399 45.4673
BICR 22 GDSC1; GDSC2; CTRP2 -10.6851 -6.0246 -10.6867 74.2643
BB30-HNC GDSC1; GDSC2 -10.0527 -7.7542 -10.1102 37.7043
Ca9-22 GDSC1; GDSC2 -10.0505 -3.8571 -10.1399 63.7189
CAL-27 GDSC1; GDSC2 -10.017 -7.6616 -10.017 64.9002
HO-1-N-1 GDSC1; GDSC2 -9.8374 -5.4014 -9.8514 63.4978
PCI-38 GDSC1 -9.795 -7.6674 -9.8472 43.632
HO-1-u-1 GDSC1; GDSC2 -9.7358 -5.1028 -10.4395 37.1567
JHU-029 GDSC1; GDSC2 -9.6225 -6.6246 -9.846 34.1857
Detroit 562 GDSC1; GDSC2 -9.4552 -6.4295 -9.4561 61.7226
SCC-25 GDSC1; GDSC2 -9.3418 7.3017 -15.7894 43.7777
BB49-HNC GDSC1; GDSC2 -8.716 0.0016 -9.2674 56.1632
CAL-33 GDSC1; GDSC2; CTRP2 -8.6983 -3.0808 -8.7143 65.4801
OSC-19 GDSC1; GDSC2 -8.4745 -4.8373 -9.1944 25.4557
BHY GDSC1; GDSC2 -8.4019 -2.0269 -10.3788 30.5881
DOK GDSC1; GDSC2 -7.9963 -1.0607 -8.286 53.2064
NCI-H3118 GDSC1; GDSC2 -7.6415 -3.3504 -7.6758 51.592
BICR 10 GDSC1; GDSC2 -7.6251 -2.7491 -7.6939 51.4796
PCI-15A GDSC1; GDSC2 -6.9104 4.3509 -12.1564 31.0322
HSC-3 GDSC1; GDSC2 -6.4413 4.0874 -7.966 46.2808
OSC-20 GDSC1; GDSC2 -5.4702 6.976 -8.0454 43.1142
PCI-04B GDSC1; GDSC2 -5.4212 8.0382 -8.4412 43.3102
BICR 56 CTRP2 -5.3439 35.4776 -18.9813 55.1375
SCC-4 GDSC1; GDSC2; CTRP2 -5.1496 8.2965 -6.8536 50.0916
PE/CA-PJ15 GDSC1; GDSC2; CTRP2 -4.0793 5.8457 -4.9502 46.0655
LB771-HNC GDSC1; GDSC2 -3.33 2.4097 -4.0248 29.4716
SKN-3 GDSC1; GDSC2 -3.1891 8.7893 -6.493 34.693
HSC-2 GDSC1; GDSC2; CTRP2 -3.0304 24.026 -11.299 46.0316
PCI-30 GDSC1; GDSC2 -1.918 7.483 -9.9908 11.6471
BICR 18 CTRP2 -1.8528 47.2397 -21.4554 50.4347
SCC-15 GDSC1; GDSC2 -1.6796 10.9767 -6.0477 30.2941
UPCI-SCC-090 GDSC1; GDSC2 -1.3607 9.2989 -4.9365 27.0653
SCC-9 GDSC1; GDSC2; CTRP2 -0.9466 21.7549 -8.1938 40.8731
SAS GDSC1; GDSC2 -0.8824 16.1739 -7.8556 31.9617
BICR 16 CTRP2 -0.308 118.4455 -55.5338 49.4677
SAT [Human HNSCC] GDSC1; GDSC2 1.2562 17.7447 -6.7704 26.1645
JHU-022 GDSC1; GDSC2 1.2628 21.2232 -8.5039 29.265
BICR 78 GDSC1; GDSC2 2.0274 20.9284 -7.7206 26.7314
HSC-4 GDSC1; GDSC2 2.5224 22.09 -7.8972 26.295
BICR 31 GDSC2; CTRP2 2.6779 26.9224 -7.3177 34.2108
PE/CA-PJ41 (clone D2) CTRP2 7.0639 30.344 -5.2666 31.561
FaDu GDSC1; GDSC2; CTRP2 8.9246 27.4192 -2.3478 18.3867
⏷ Show the Full List of 48 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 20 Cell Line(s) in Urinary Tract Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
5637 GDSC1; GDSC2 -11.5105 -3.8815 -11.6667 69.3392
BFTC-905 GDSC1; GDSC2 -10.2143 -5.706 -10.2273 65.4774
RT-112 GDSC1; GDSC2 -8.7536 -5.7644 -8.755 57.8222
CAL-29 GDSC1; GDSC2 -8.2967 -2.5281 -8.4157 54.9441
UM-UC-3 GDSC1; GDSC2 -7.6369 -4.3277 -8.5514 18.4222
639V GDSC1; GDSC2 -7.0108 -0.2126 -7.3733 48.2974
647V GDSC1; GDSC2 -6.7973 -0.5307 -7.0842 47.1619
BC-3C CTRP2 -5.4627 10.6233 -8.0059 62.3442
SW780 GDSC1; GDSC2 -5.0023 3.2627 -6.1232 39.2041
KU-19-19 GDSC1; GDSC2 -4.4884 7.6108 -7.2918 39.3946
U-BLC1 CTRP2 -4.4506 17.7557 -9.861 57.0291
SW1710 GDSC1; GDSC2 -4.1835 10.7403 -8.3819 39.8975
T24 GDSC1; GDSC2; CTRP2 -4.1169 1.9354 -4.2512 45.6589
HT-1376 GDSC1; GDSC2 -1.1217 5.6513 -8.7314 5.0276
KMBC-2 CTRP2 0.9373 85.8444 -38.1876 48.454
RT-4 GDSC1; GDSC2 1.0952 12.8729 -4.4722 21.0417
TCCSUP GDSC1; GDSC2 4.0818 20.0029 -5.635 19.3486
J82 GDSC1; GDSC2; CTRP2 5.7696 20.0841 -1.2057 19.8717
HT-1197 GDSC1; GDSC2; CTRP2 9.5438 25.9747 -1.1762 15.2422
UM-UC-1 CTRP2 12.9668 47.8027 -9.3841 29.0204
⏷ Show the Full List of 20 Cancer Drug Sensitivity Data of This Drug
Cancer Drug Sensitivity Data Curated from 39 Cell Line(s) in Urogenital System Tissue
Cell Line Original Dataset IC50 IC90 EC50 AUC
SW954 GDSC1; GDSC2 -9.7901 -6.2399 -10.1296 36.3083
NT2-D1 GDSC1; GDSC2 -9.3968 -5.7528 -9.8487 33.0187
CAL-39 GDSC1; GDSC2 -9.0605 -6.5184 -9.0608 59.5537
PA-1 GDSC1; GDSC2 -9.0154 -5.5511 -9.0192 59.2365
BPH-1 GDSC1; GDSC2 -8.9141 -3.074 -9.0146 58.1295
JAR GDSC1; GDSC2 -8.6226 -6.8476 -8.7112 23.5433
PWR-1E GDSC1; GDSC2 -8.5028 -2.9753 -8.5925 56.0742
ACC-OV7 GDSC1; GDSC2 -8.3364 -3.4307 -9.6627 27.2164
KGN GDSC1; GDSC2 -8.2956 -2.6809 -9.9677 28.4442
NCC-IT GDSC2 -8.2953 -6.5702 -8.4132 20.4162
HeLa GDSC1; GDSC2; CTRP2 -8.2547 -5.258 -8.2548 64.0147
MS751 GDSC1; GDSC2 -7.8307 -1.4235 -8.053 52.4437
TC-YIK GDSC1; GDSC2 -7.6403 -4.4299 -7.6456 51.6117
JEG-3 GDSC1; GDSC2 -7.4119 -4.1443 -8.4135 16.756
NEC8 GDSC1; GDSC2 -7.2722 5.2525 -9.2826 49.7113
OVCA433 GDSC1; GDSC2 -7.2535 1.1162 -10.8432 28.0441
UWB1.289 GDSC1; GDSC2 -6.8249 -4.3909 -7.7331 10.5108
OMC-1 [Human cervical carcinoma] GDSC1; GDSC2 -6.3945 -1.5153 -8.7859 15.5553
Ca Ski GDSC1; GDSC2 -6.1824 5.7166 -8.2929 45.5773
C-33 A GDSC1; GDSC2 -5.9873 1.6707 -6.7024 43.4828
SW962 GDSC1; GDSC2 -5.7362 -2.1935 -7.9206 8.5181
DoTc2 4510 GDSC1; GDSC2 -5.5229 -0.1721 -5.7726 40.3247
SiSo GDSC1; GDSC2 -5.2998 1.0477 -5.7889 39.5927
ME-180 GDSC1; GDSC2 -4.307 5.4491 -6.1969 37.1945
PEO1 GDSC1; GDSC2 -2.8139 5.8191 -4.7882 30.1219
C-4-I GDSC1; GDSC2 -2.4826 9.2437 -6.0009 32.029
OVMIU GDSC1; GDSC2 -0.9914 12.933 -6.3571 29.4748
JHOS-3 GDSC1; GDSC2 -0.9476 7.0815 -9.2522 7.037
LB831-BLC GDSC1; GDSC2 -0.7525 18.6478 -8.965 33.368
OV17R GDSC1; GDSC2 -0.6038 5.3789 -8.3711 3.0704
SiHa GDSC1; GDSC2 0.08 15.8623 -6.8436 28.3694
SKN GDSC1; GDSC2 0.1875 18.2061 -7.9171 30.1061
OVCA420 GDSC1; GDSC2 0.2623 5.2589 -1.4443 13.0419
HEY GDSC1; GDSC2 0.6085 12.456 -4.6843 22.4813
DSH1 GDSC1; GDSC2 0.6089 11.1709 -4.0439 20.7238
HEC-1 GDSC1; GDSC2 0.8781 12.155 -4.3001 20.9553
SKG-IIIa GDSC1; GDSC2 1.1869 16.2659 -6.0898 24.8488
HT-3 GDSC1; GDSC2 4.6866 18.9802 -4.6827 16.1571
SW756 GDSC1; GDSC2 8.4718 27.4168 -6.141 15.2658
⏷ Show the Full List of 39 Cancer Drug Sensitivity Data of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Same Disease as Docetaxel
DDI Drug Name DDI Drug ID Severity Mechanism Disease REF
Larotrectinib DM26CQR Moderate Decreased metabolism of Docetaxel caused by Larotrectinib mediated inhibition of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [26]
Armodafinil DMGB035 Minor Increased metabolism of Docetaxel caused by Armodafinil mediated induction of CYP450 enzyme. Solid tumour/cancer [2A00-2F9Z] [27]
LEE011 DMMX75K Moderate Decreased clearance of Docetaxel due to the transporter inhibition by LEE011. Solid tumour/cancer [2A00-2F9Z] [26]
Coadministration of a Drug Treating the Disease Different from Docetaxel (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Moderate Increased metabolism of Docetaxel caused by Ivosidenib mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [26]
Midostaurin DMI6E0R Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Midostaurin. Acute myeloid leukaemia [2A60] [28]
Arn-509 DMT81LZ Moderate Increased metabolism of Docetaxel caused by Arn-509 mediated induction of CYP450 enzyme. Acute myeloid leukaemia [2A60] [26]
Gilteritinib DMTI0ZO Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Gilteritinib. Acute myeloid leukaemia [2A60] [29]
Dronedarone DMA8FS5 Major Decreased clearance of Docetaxel due to the transporter inhibition by Dronedarone. Angina pectoris [BA40] [26]
Posaconazole DMUL5EW Major Decreased clearance of Docetaxel due to the transporter inhibition by Posaconazole. Aspergillosis [1F20] [26]
Roflumilast DMPGHY8 Moderate Additive immunosuppressive effects by the combination of Docetaxel and Roflumilast. Asthma [CA23] [28]
Dalfopristin DM4LTKV Moderate Decreased metabolism of Docetaxel caused by Dalfopristin mediated inhibition of CYP450 enzyme. Bacterial infection [1A00-1C4Z] [26]
ABT-492 DMJFD2I Minor Decreased absorption of Docetaxel due to intestinal mucosa variation caused by ABT-492. Bacterial infection [1A00-1C4Z] [30]
Troleandomycin DMUZNIG Major Decreased clearance of Docetaxel due to the transporter inhibition by Troleandomycin. Bacterial infection [1A00-1C4Z] [26]
Erdafitinib DMI782S Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Erdafitinib. Bladder cancer [2C94] [31]
Lapatinib DM3BH1Y Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Lapatinib. Breast cancer [2C60-2C6Y] [26]
Tucatinib DMBESUA Major Decreased clearance of Docetaxel due to the transporter inhibition by Tucatinib. Breast cancer [2C60-2C6Y] [26]
Palbociclib DMD7L94 Moderate Decreased metabolism of Docetaxel caused by Palbociclib mediated inhibition of CYP450 enzyme. Breast cancer [2C60-2C6Y] [26]
Osilodrostat DMIJC9X Moderate Decreased metabolism of Docetaxel caused by Osilodrostat mediated inhibition of CYP450 enzyme. Cushing syndrome [5A70] [26]
Ivacaftor DMZC1HS Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Ivacaftor. Cystic fibrosis [CA25] [26]
MK-8228 DMOB58Q Moderate Decreased metabolism of Docetaxel caused by MK-8228 mediated inhibition of CYP450 enzyme. Cytomegaloviral disease [1D82] [26]
Cenobamate DM8KLU9 Moderate Increased metabolism of Docetaxel caused by Cenobamate mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Stiripentol DMMSDOY Major Decreased metabolism of Docetaxel caused by Stiripentol mediated inhibition of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Fosphenytoin DMOX3LB Moderate Increased metabolism of Docetaxel caused by Fosphenytoin mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Rufinamide DMWE60C Moderate Increased metabolism of Docetaxel caused by Rufinamide mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [28]
Eslicarbazepine DMZREFQ Moderate Increased metabolism of Docetaxel caused by Eslicarbazepine mediated induction of CYP450 enzyme. Epilepsy/seizure [8A61-8A6Z] [26]
Boceprevir DMBSHMF Major Decreased clearance of Docetaxel due to the transporter inhibition by Boceprevir. Hepatitis virus infection [1E50-1E51] [26]
Simeprevir DMLUA9D Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Simeprevir. Hepatitis virus infection [1E50-1E51] [26]
Telaprevir DMMRV29 Major Decreased clearance of Docetaxel due to the transporter inhibition by Telaprevir. Hepatitis virus infection [1E50-1E51] [26]
Brentuximab vedotin DMWLC57 Moderate Increased risk of peripheral neuropathy by the combination of Docetaxel and Brentuximab vedotin. Hodgkin lymphoma [2B30] [32]
Fosamprenavir DM4W9B3 Major Decreased metabolism of Docetaxel caused by Fosamprenavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [26]
Cobicistat DM6L4H2 Major Decreased clearance of Docetaxel due to the transporter inhibition by Cobicistat. Human immunodeficiency virus disease [1C60-1C62] [26]
Etravirine DMGV8QU Moderate Increased metabolism of Docetaxel caused by Etravirine mediated induction of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [26]
Darunavir DMN3GCH Moderate Decreased metabolism of Docetaxel caused by Darunavir mediated inhibition of CYP450 enzyme. Human immunodeficiency virus disease [1C60-1C62] [26]
Teriflunomide DMQ2FKJ Major Additive immunosuppressive effects by the combination of Docetaxel and Teriflunomide. Hyper-lipoproteinaemia [5C80] [33]
Tolvaptan DMIWFRL Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Tolvaptan. Hypo-osmolality/hyponatraemia [5C72] [29]
Berotralstat DMWA2DZ Moderate Decreased metabolism of Docetaxel caused by Berotralstat mediated inhibition of CYP450 enzyme. Innate/adaptive immunodeficiency [4A00] [26]
Amobarbital DM0GQ8N Moderate Increased metabolism of Docetaxel caused by Amobarbital mediated induction of CYP450 enzyme. Insomnia [7A00-7A0Z] [26]
Denosumab DMNI0KO Moderate Additive immunosuppressive effects by the combination of Docetaxel and Denosumab. Low bone mass disorder [FB83] [34]
Crizotinib DM4F29C Major Decreased clearance of Docetaxel due to the transporter inhibition by Crizotinib. Lung cancer [2C25] [26]
Brigatinib DM7W94S Moderate Increased metabolism of Docetaxel caused by Brigatinib mediated induction of CYP450 enzyme. Lung cancer [2C25] [35]
Ceritinib DMB920Z Major Decreased metabolism of Docetaxel caused by Ceritinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [26]
PF-06463922 DMKM7EW Moderate Increased metabolism of Docetaxel caused by PF-06463922 mediated induction of CYP450 enzyme. Lung cancer [2C25] [26]
Osimertinib DMRJLAT Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Osimertinib. Lung cancer [2C25] [26]
Capmatinib DMYCXKL Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Capmatinib. Lung cancer [2C25] [36]
Selpercatinib DMZR15V Moderate Decreased metabolism of Docetaxel caused by Selpercatinib mediated inhibition of CYP450 enzyme. Lung cancer [2C25] [26]
Idelalisib DM602WT Major Decreased metabolism of Docetaxel caused by Idelalisib mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [26]
IPI-145 DMWA24P Moderate Decreased metabolism of Docetaxel caused by IPI-145 mediated inhibition of CYP450 enzyme. Mature B-cell leukaemia [2A82] [26]
Vemurafenib DM62UG5 Moderate Increased metabolism of Docetaxel caused by Vemurafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [26]
LGX818 DMNQXV8 Moderate Increased metabolism of Docetaxel caused by LGX818 mediated induction of CYP450 enzyme. Melanoma [2C30] [37]
Dabrafenib DMX6OE3 Moderate Increased metabolism of Docetaxel caused by Dabrafenib mediated induction of CYP450 enzyme. Melanoma [2C30] [26]
Danazol DML8KTN Moderate Decreased metabolism of Docetaxel caused by Danazol mediated inhibition of CYP450 enzyme. Menstrual cycle bleeding disorder [GA20] [26]
Lasmiditan DMXLVDT Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Lasmiditan. Migraine [8A80] [38]
Exjade DMHPRWG Moderate Decreased metabolism of Docetaxel caused by Exjade mediated inhibition of CYP450 enzyme. Mineral absorption/transport disorder [5C64] [39]
Tecfidera DM2OVDT Moderate Additive immunosuppressive effects by the combination of Docetaxel and Tecfidera. Multiple sclerosis [8A40] [40]
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Docetaxel and Siponimod. Multiple sclerosis [8A40] [29]
Fingolimod DM5JVAN Major Additive immunosuppressive effects by the combination of Docetaxel and Fingolimod. Multiple sclerosis [8A40] [41]
Ocrelizumab DMEZ2KH Moderate Additive immunosuppressive effects by the combination of Docetaxel and Ocrelizumab. Multiple sclerosis [8A40] [42]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Docetaxel and Ozanimod. Multiple sclerosis [8A40] [28]
Fedratinib DM4ZBK6 Moderate Decreased metabolism of Docetaxel caused by Fedratinib mediated inhibition of CYP450 enzyme. Myeloproliferative neoplasm [2A20] [26]
Dasatinib DMJV2EK Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Dasatinib. Myeloproliferative neoplasm [2A20] [26]
Omacetaxine mepesuccinate DMPU2WX Moderate Additive immunosuppressive effects by the combination of Docetaxel and Omacetaxine mepesuccinate. Myeloproliferative neoplasm [2A20] [43]
Rolapitant DM8XP26 Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Rolapitant. Nausea/vomiting [MD90] [44]
Netupitant DMEKAYI Moderate Decreased metabolism of Docetaxel caused by Netupitant mediated inhibition of CYP450 enzyme. Nausea/vomiting [MD90] [26]
Entrectinib DMMPTLH Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Entrectinib. Non-small cell lung cancer [2C25] [26]
Rucaparib DM9PVX8 Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Rucaparib. Ovarian cancer [2C73] [26]
Abametapir DM2RX0I Moderate Decreased metabolism of Docetaxel caused by Abametapir mediated inhibition of CYP450 enzyme. Pediculosis [1G00] [45]
Lefamulin DME6G97 Moderate Decreased metabolism of Docetaxel caused by Lefamulin mediated inhibition of CYP450 enzyme. Pneumonia [CA40] [46]
Lonafarnib DMGM2Z6 Major Decreased clearance of Docetaxel due to the transporter inhibition by Lonafarnib. Premature ageing appearance [LD2B] [26]
Enzalutamide DMGL19D Moderate Increased metabolism of Docetaxel caused by Enzalutamide mediated induction of CYP450 enzyme. Prostate cancer [2C82] [26]
Temsirolimus DMS104F Moderate Increased plasma concentrations of Docetaxel and Temsirolimus due to competitive inhibition of the same metabolic pathway. Renal cell carcinoma [2C90] [47]
Canakinumab DM8HLO5 Moderate Additive immunosuppressive effects by the combination of Docetaxel and Canakinumab. Rheumatoid arthritis [FA20] [48]
Rilonacept DMGLUQS Moderate Additive immunosuppressive effects by the combination of Docetaxel and Rilonacept. Rheumatoid arthritis [FA20] [48]
Golimumab DMHZV7X Major Additive immunosuppressive effects by the combination of Docetaxel and Golimumab. Rheumatoid arthritis [FA20] [49]
Anthrax vaccine DM9GSWY Moderate Antagonize the effect of Docetaxel when combined with Anthrax vaccine. Sepsis [1G40-1G41] [50]
Voxelotor DMCS6M5 Moderate Decreased clearance of Docetaxel due to the transporter inhibition by Voxelotor. Sickle-cell disorder [3A51] [26]
Telotristat ethyl DMDIYFZ Moderate Increased metabolism of Docetaxel caused by Telotristat ethyl mediated induction of CYP450 enzyme. Small intestine developmental anomaly [DA90] [28]
Fostamatinib DM6AUHV Moderate Decreased metabolism of Docetaxel caused by Fostamatinib mediated inhibition of CYP450 enzyme. Thrombocytopenia [3B64] [51]
Brilinta DMBR01X Moderate Decreased metabolism of Docetaxel caused by Brilinta mediated inhibition of CYP450 enzyme. Thrombosis [DB61-GB90] [26]
Valganciclovir DMS2IUH Moderate Additive myelosuppressive effects by the combination of Docetaxel and Valganciclovir. Virus infection [1A24-1D9Z] [29]
⏷ Show the Full List of 76 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Citric acid monohydrate E00271 22230 Acidulant; Antioxidant; Buffering agent; Complexing agent; Flavoring agent
Ethanol E00023 702 Antimicrobial preservative; Penetration agent; Solvent
Polysorbate 80 E00665 Not Available Dispersing agent; Emollient; Emulsifying agent; Plasticizing agent; Solubilizing agent; Surfactant; Suspending agent
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Docetaxel 20mg/2ml injectable 20mg/2ml Injectable Injection
Docetaxel 80mg/4ml injectable 80mg/4ml Injectable Injection
Docetaxel 160mg/8ml injectable 160mg/8ml Injectable Injection
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 Docetaxel FDA Label
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6809).
3 BDDCS applied to over 900 drugs
4 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
5 Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
6 Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia. Cancer Sci. 2008 May;99(5):967-72.
7 Docetaxel: a review of its use in metastatic breast cancer. Drugs. 2005;65(17):2513-31.
8 RNA-sequencing dissects the transcriptome of polyploid cancer cells that are resistant to combined treatments of cisplatin with paclitaxel and docetaxel. Mol Biosyst. 2017 Sep 26;13(10):2125-2134.
9 Modulation of the ATPase and transport activities of broad-acting multidrug resistance factor ABCC10 (MRP7). Cancer Res. 2012 Dec 15;72(24):6457-67.
10 Transport of diclofenac by breast cancer resistance protein (ABCG2) and stimulation of multidrug resistance protein 2 (ABCC2)-mediated drug transport by diclofenac and benzbromarone. Drug Metab Dispos. 2009 Jan;37(1):129-36.
11 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
12 Ixabepilone, a novel microtubule-targeting agent for breast cancer, is a substrate for P-glycoprotein (P-gp/MDR1/ABCB1) but not breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 2011 May;337(2):423-32.
13 FDA Drug Development and Drug Interactions
14 Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett. 2008 Feb 18;260(1-2):163-9.
15 Effect of ABCB1 C3435T polymorphism on docetaxel pharmacokinetics according to menopausal status in breast cancer patients. Br J Cancer. 2010 Aug 10;103(4):560-6.
16 Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol. 2005 Feb 20;23(6):1061-9.
17 Drug Interactions Flockhart Table
18 Anti-cancer effects of novel flavonoid vicenin-2 as a single agent and in synergistic combination with docetaxel in prostate cancer. Biochem Pharmacol. 2011 Nov 1;82(9):1100-9. doi: 10.1016/j.bcp.2011.07.078. Epub 2011 Jul 23.
19 Enhanced Bax in oral SCC in relation to antitumor effects of chemotherapy. J Oral Pathol Med. 2005 Feb;34(2):93-9. doi: 10.1111/j.1600-0714.2004.00257.x.
20 Enhanced chemotherapeutic efficacy of docetaxel in human lung cancer cell line via GLUT1 inhibitor. J Biochem Mol Toxicol. 2023 Jun;37(6):e23348. doi: 10.1002/jbt.23348. Epub 2023 Mar 31.
21 Down-regulation of intratumoral aromatase messenger RNA levels by docetaxel in human breast cancers. Clin Cancer Res. 2004 Dec 15;10(24):8163-9.
22 Pharmacogenomics variation in drug metabolizing enzymes and transporters in relation to docetaxel toxicity in Lebanese breast cancer patients: paving the way for OMICs in low and middle income countries. OMICS. 2013 Jul;17(7):353-67. doi: 10.1089/omi.2013.0019. Epub 2013 Jun 11.
23 Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer. 2004 Sep 10;111(4):617-26. doi: 10.1002/ijc.20289.
24 [Antisense RNA targeting survivin enhances the chemosensitivity of LOVO/Adr cells to taxotere]. Zhonghua Wei Chang Wai Ke Za Zhi. 2005 Sep;8(5):455-8.
25 Docetaxel-induced apoptosis of human melanoma is mediated by activation of c-Jun NH2-terminal kinase and inhibited by the mitogen-activated protein kinase extracellular signal-regulated kinase 1/2 pathway. Clin Cancer Res. 2007 Feb 15;13(4):1308-14. doi: 10.1158/1078-0432.CCR-06-2216.
26 Aronson JK, Grahame-Smith DG "Clinical pharmacology: adverse drug interactions." Br Med J 282 (1981): 288-91. [PMID: 6779990]
27 Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
28 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
29 Cerner Multum, Inc. "Australian Product Information.".
30 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
31 Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
32 Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
33 Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
34 Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
35 Product Information. Alunbrig (brigatinib). Ariad Pharmaceuticals Inc, Cambridge, MA.
36 Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
37 Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
38 Product Information. Reyvow (lasmiditan). Lilly, Eli and Company, Indianapolis, IN.
39 Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
40 Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
41 Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
42 Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
43 Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
44 Product Information. Varubi (rolapitant). Tesaro Inc., Waltham, MA.
45 Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
46 Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
47 Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
48 Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
49 Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
50 CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]
51 Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.